Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-(dimethylamino)-ethanol + ATP
ADP + 2-(dimethylamino)-ethyl phosphate
2-aminoethanol + ATP
ADP + 2-aminoethyl phosphate
-
-
-
-
?
2-methylaminoethanol + ATP
ADP + 2-methylaminoethyl phosphate
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
ATP + choline
ADP + phosphocholine
ATP + dimethylethanolamine
ADP + phosphodimethylethanolamine
-
-
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
ATP + ethanolamine
ADP + O-phosphoethanolamine
ATP + ethanolamine
ADP + phosphoethanolamine
-
-
-
-
?
beta-methylcholine + ATP
ADP + beta-methylcholine phosphate
-
-
-
-
?
choline + ATP
O-phosphocholine + ADP
choline + ATP
phosphocholine + ADP
choline + ATP
phosphorylcholine + ADP
-
-
-
?
CTP + choline
CDP + choline phosphate
-
12% of the activity with ATP
-
-
?
diethanolamine + ATP
ADP + O-phospho-diethanolamine
-
-
-
-
?
ethanolamine + ATP
ADP + ethanolamine phosphate
ethanolamine + ATP
O-phosphoethanolamine + ADP
-
first step in the biosynthesis of the glycerophospholipid glycerophosphoethanolamine
-
-
?
ethanolamine + ATP
phosphoethanolamine + ADP
-
-
-
?
GTP + choline
GDP + choline phosphate
N,N,N-triethylethanolamine + ATP
ADP + N,N,N-triethylethanolamine phosphate
-
weak
-
-
?
N,N-diethyl-N-methylethanolamine + ATP
ADP + N,N-diethyl-N-methylethanolamine phosphate
-
weak
-
-
?
N,N-diethylethanolamine + ATP
ADP + N,N-diethylethanolamine phosphate
N,N-diethylethanolamine + ATP
ADP + O-phospho-N-diethylethanolamine
-
-
-
-
?
N,N-diisopropylethanolamine + ATP
ADP + N,N-diisopropylethanolamine phosphate
-
-
-
-
?
N,N-dimethyl-N-propylethanolamine + ATP
ADP + N,N-dimethyl-N-propylethanolamine phosphate
-
-
-
-
?
N,N-dimethylaminopropanol + ATP
ADP + N,N-dimethylaminopropyl phosphate
-
-
-
-
?
N,N-dimethylethanolamine + ATP
ADP + N,N-dimethylethanolamine phosphate
N,N-dimethylethanolamine + ATP
ADP + O-phospho-N,N-dimethylethanolamine
-
-
-
-
?
N,N-dimethylethylcholine + ATP
ADP + N,N-dimethylethylcholine phosphate
-
-
-
-
?
N,N-dimethylisopropylcholine + ATP
ADP + N,N-dimethylisopropylcholine phosphate
-
-
-
-
?
N,N-dimethylpropylcholine + ATP
ADP + N,N-dimethylpropylcholine phosphate
-
-
-
-
?
N-ethylethanolamine + ATP
ADP + O-phospho-N-ethylethanolamine
-
-
-
-
?
N-methylethanolamine + ATP
ADP + N-methylethanolamine phosphate
N-methylethanolamine + ATP
ADP + O-phospho-N-methylethanolamine
-
-
-
-
?
N-monoethylethanolamine + ATP
ADP + N-monoethylethanolamine phosphate
-
-
-
-
?
N-monomethylethanolamine + ATP
ADP + N-monomethylethanolamine phosphate
UTP + choline
UDP + choline phosphate
additional information
?
-
2-(dimethylamino)-ethanol + ATP
ADP + 2-(dimethylamino)-ethyl phosphate
-
-
-
-
?
2-(dimethylamino)-ethanol + ATP
ADP + 2-(dimethylamino)-ethyl phosphate
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the Kennedy pathway, that yields phosphatidylcholine as final product, increased activity under salt stress and cold conditions
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the CDP-choline pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial enzyme of the CDP-choline pathway and the CDP-ethanolamine pathway
-
-
?
ATP + choline
ADP + O-phosphocholine
-
choline pathway or CDP-ethanolamine pathway is so-called Kennedy pathway
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the CDP-choline pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction, possible role in carcinogenesis
-
-
?
ATP + choline
ADP + O-phosphocholine
initial step of the Kennedy pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction, the product O-phosphocholine serves as second messenger and is essential for cell growth, enzyme plays a role in tumor generation
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
the catalytic efficiency (Vmax/Km) using choline as substrate is 2000fold greater than the efficiency using ethanolamine as substrate
-
-
?
ATP + choline
ADP + O-phosphocholine
the catalytic efficiency (Vmax/Km) using choline as substrate is 2000fold greater than the efficiency using ethanolamine as substrate
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the CDP-choline pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction, involved in cell stress response
-
-
?
ATP + choline
ADP + O-phosphocholine
initial step of the Kennedy pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
enzyme of the CDP-choline pathway of lecithin biosynthesis
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
641347, 641348, 641349, 641352, 641359, 641360, 641366, 641368, 641370, 641371, 641372, 663274, 673201 -
-
?
ATP + choline
ADP + O-phosphocholine
-
both isoforms
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial enzyme of the CDP-choline pathway and the CDP-ethanolamine pathway
-
-
?
ATP + choline
ADP + O-phosphocholine
-
choline pathway or CDP-ethanolamine pathway is so-called Kennedy pathway
-
-
?
ATP + choline
ADP + O-phosphocholine
-
enzyme of the CDP-choline pathway of lecithin biosynthesis
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the CDP-choline pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction and cell stress regulation
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
r
ATP + choline
ADP + O-phosphocholine
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
r
ATP + choline
ADP + O-phosphocholine
-
initial enzyme of the CDP-choline pathway and the CDP-ethanolamine pathway
-
-
?
ATP + choline
ADP + O-phosphocholine
-
initial step of the CDP-choline pathway, that yields phosphatidylcholine as final product, involved in mitogenic signaling transduction
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + O-phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
transfer of the gamma-phosphoryl group of ATP
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
?
ATP + choline
ADP + phosphocholine
-
-
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
-
poor substrate compared to choline
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
-
can not phosphorylate ethanolamine efficiently
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
-
-
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
-
not: basic isoform
-
-
?
ATP + ethanolamine
ADP + ethanolamine phosphate
-
poor substrate compared to choline
-
-
?
ATP + ethanolamine
ADP + O-phosphoethanolamine
-
-
-
?
ATP + ethanolamine
ADP + O-phosphoethanolamine
-
-
-
?
choline + ATP
O-phosphocholine + ADP
-
-
-
?
choline + ATP
O-phosphocholine + ADP
-
first step in the biosynthesis of the glycerophospholipid glycerophosphocholine
-
-
?
choline + ATP
phosphocholine + ADP
-
-
-
-
?
choline + ATP
phosphocholine + ADP
-
-
-
?
choline + ATP
phosphocholine + ADP
-
catalyzes the first phosphorylation reaction in the Kennedy pathway (biosynthesis of the major membrane phospholipid phosphatidylcholine)
-
-
?
choline + ATP
phosphocholine + ADP
first enzyme in the CDP-choline (Kennedy) pathway for the biosynthesis of phosphatidylcholine
choline kinase supply phosphocholine for the biosynthesis of phosphatidylcholine that is essential for growth and cell division
-
?
choline + ATP
phosphocholine + ADP
-
choline kinase may have a regulatory role in phosphatidylcholine biosynthesis
-
-
?
choline + ATP
phosphocholine + ADP
-
The induction of CKI1 expression in zinc-depleted cells translated into increased choline kinase activity in vitro and in vivo and in an increase in phosphatidylcholine synthesis via the Kennedy pathway
-
-
?
ethanolamine + ATP
ADP + ethanolamine phosphate
-
-
-
-
?
ethanolamine + ATP
ADP + ethanolamine phosphate
-
-
-
-
?
GTP + choline
GDP + choline phosphate
-
at 50% of the activity with ATP
-
-
?
GTP + choline
GDP + choline phosphate
-
poor substrate
-
-
?
GTP + choline
GDP + choline phosphate
-
at 50% of the activity with ATP
-
-
?
N,N-diethylethanolamine + ATP
ADP + N,N-diethylethanolamine phosphate
-
-
-
-
?
N,N-diethylethanolamine + ATP
ADP + N,N-diethylethanolamine phosphate
-
-
-
-
?
N,N-dimethylethanolamine + ATP
ADP + N,N-dimethylethanolamine phosphate
-
-
-
-
?
N,N-dimethylethanolamine + ATP
ADP + N,N-dimethylethanolamine phosphate
-
not: basic isoform
-
-
?
N,N-dimethylethanolamine + ATP
ADP + N,N-dimethylethanolamine phosphate
-
-
-
-
?
N-methylethanolamine + ATP
ADP + N-methylethanolamine phosphate
-
-
-
-
?
N-methylethanolamine + ATP
ADP + N-methylethanolamine phosphate
-
not: basic isoform
-
-
?
N-monomethylethanolamine + ATP
ADP + N-monomethylethanolamine phosphate
-
-
-
-
?
N-monomethylethanolamine + ATP
ADP + N-monomethylethanolamine phosphate
-
-
-
-
?
UTP + choline
UDP + choline phosphate
-
at 20% of the activity with ATP
-
-
?
UTP + choline
UDP + choline phosphate
-
poor substrate
-
-
?
UTP + choline
UDP + choline phosphate
-
at 20% of the activity with ATP
-
-
?
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
detection via quantitative TLC
-
-
-
additional information
?
-
-
specificity overview
-
-
?
additional information
?
-
-
microarray analysis detected changes in the expression of 33 proliferation-related genes with Chk down-regulation
-
-
?
additional information
?
-
usage of a coupled assay method with pyruvate kinase, and lactate dehydrogenase, at pH 7.5 and 37°C
-
-
-
additional information
?
-
-
usage of a coupled assay method with pyruvate kinase, and lactate dehydrogenase, at pH 7.5 and 37°C
-
-
-
additional information
?
-
-
specificity overview
-
-
?
additional information
?
-
-
specificity overview
-
-
?
additional information
?
-
-
specificity overview
-
-
?
additional information
?
-
-
specificity overview
-
-
?
additional information
?
-
-
Further substrate specificity analysis reveals that TbC/EK2 are able to tolerate various modifications at the amino group, with the exception of a quaternary amine for TbEK1 (choline). The enzyme recognizes analogues with substituents on C-2, but substitutions on C-1 and elongations of the carbon chain are not well tolerate. Secondary and tertiary amino modifications are better than choline. A reduction of activity is seen with the elongation of the carbon chain, but it is not abolished even when increased by an ethylene unit. Modifications at the hydroxy group result in no detectable reactivity.
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-azabicyclo[2.2.2]octan-3-yl)bis(5-chlorothiophen-2-yl)methanol
(1S)-1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-[(oxan-4-yl)oxy]phenyl]-1-phenylpropan-1-ol
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
(azepan-1-yl)(piperazin-1-yl)methanone
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[(4-dimethylamino)pyridinium] tribromide
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[4-(3,5-dichloro-N-methylanilino)pyridinium] tribromide
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[4-(4-chloro-N-methylanilino)pyridinium] tribromide
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[4-(N-methylanilino)pyridinium] tribromide
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[4-(piperidino)pyridinium] tribromide
-
1,1',1''-(benzene-1,3,5-triylmethylene)tris[4-(pyrrolidino)pyridinium] tribromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(3-hydroxyquinuclidinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)pyridinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)-7-chloroquinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(methyl(phenyl)amino)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(pyrrolidin-1-yl)pyridinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-((4-chlorophenyl)(methyl)amino)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(methyl(phenyl)amino)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(pyrrolidin-1-yl)quinolinium) bromide
-
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(quinuclidinium) bromide
-
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
-
IC50: 0.0528 mM
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
-
IC50: 0.0842 mM
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0084 mM
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0072 mM
1,1'-(benzene-1,3-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
-
IC50: 0.0375 mM
1,1'-(benzene-1,3-diylmethylene)bis[(4-dimethylamino)pyridinium] dibromide
-
1,1'-(benzene-1,3-diylmethylene)bis[4-(N-methylanilino)pyridinium] dibromide
-
1,1'-(benzene-1,3-diylmethylene)bis[4-(piperidino)pyridinium] dibromide
-
1,1'-(benzene-1,3-diylmethylene)bis[4-(pyrrolidino)pyridinium] dibromide
-
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
-
IC50: 0.0377 mM
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
-
IC50: 0.024 mM
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0097 mM
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0029 mM
1,1'-(benzene-1,4-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
-
IC50: 0.015 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-amino-3-methylquinolinium) dibromide
-
IC50: 0.0119 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-amino-7-chloroquinolinium) dibromide
-
IC50: 0.0206 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-aminoquinolinium) dibromide
-
IC50: 0.0012 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-azepan-1-ylquinolinium) dibromide
-
IC50: 0.0005 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
-
IC50: 0.0019 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
-
IC50: 0.0058 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0026 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0015 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.0021 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
-
IC50: 0.147 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
-
IC50: 0.0012 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.0057 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.0044 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-(phenylamino)quinolinium] dibromide
-
IC50: 0.0013 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
-
IC50: 0.00043 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0004 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0568 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.0096 mM
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0031 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-amino-3-methylquinolinium) dibromide
-
IC50: above 0.2 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-amino-7-chloroquinolinium) dibromide
-
IC50: 0.0633 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-aminoquinolinium) dibromide
-
IC50: 0.0811 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-azepan-1-ylquinolinium) dibromide
-
IC50: 0.0022 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
-
IC50: 0.0088 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
-
IC50: 0.0111 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0034 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0018 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.002 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
-
IC50: 0.0461 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
-
IC50: 0.0198 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.0114 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.0397 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-(phenylamino)quinolinium] dibromide
-
IC50: 0.0178 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
-
IC50: 0.0043 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.003 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0961 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.0206 mM
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0114 mM
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis(4-aminoquinolinium)
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis(4-azepan-1-ylquinolinium)
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-(dimethylamino)quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-(phenylamino)quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-[methyl(phenyl)amino]quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-(dimethylamino)quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-3,3'-diylbis(4-amino-3-methylquinolinium)
-
1,1'-biphenyl-3,3'-diylbis(4-amino-7-chloroquinolinium)
-
1,1'-biphenyl-3,3'-diylbis(4-aminoquinolinium)
-
1,1'-biphenyl-3,3'-diylbis(4-azepan-1-ylquinolinium)
-
1,1'-biphenyl-3,3'-diylbis(7-chloro-4-pyrrolidin-1-ylquinolinium)
-
1,1'-biphenyl-3,3'-diylbis[4-(dimethylamino)quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[4-(phenylamino)quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
-
1,1'-biphenyl-3,3'-diylbis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-(dimethylamino)quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-4,4'-diylbis(4-amino-7-chloroquinolinium)
-
1,1'-biphenyl-4,4'-diylbis(4-aminoquinolinium)
-
1,1'-biphenyl-4,4'-diylbis(4-azepan-1-ylquinolinium)
-
1,1'-biphenyl-4,4'-diylbis(7-chloro-4-pyrrolidin-1-ylquinolinium)
-
1,1'-biphenyl-4,4'-diylbis[4-(dimethylamino)quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[4-(phenylamino)quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
-
1,1'-biphenyl-4,4'-diylbis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-(dimethylamino)quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
-
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
-
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-piperidin-1-ylpyridinium) dibromide
-
IC50: 0.098 mM
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-pyrrolidin-1-ylpyridinium) dibromide
-
IC50: above 0.1 mM
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
-
IC50: 0.0482 mM; IC50: above 0.1 mM
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis[4-[(phenylamino)methyl]pyridinium] dibromide
-
IC50: above 0.1 mM
1,1'-[butane-1,4-diylbis[(4,1-phenylene)methylene]]bis[4-(dimethylamino)pyridin-1-ium]
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-amino-7-chloroquinolinium) dibromide
-
IC50: above 0.2 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-aminoquinolinium) dibromide
-
IC50: 0.08 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-azepan-1-ylquinolinium) dibromide
-
IC50: 0.006 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.0048 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
-
IC50: 0.0575 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
-
IC50: 0.001 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
-
IC50: 0.0057 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.0102 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-(phenylamino)quinolinium] dibromide
-
IC50: 0.0023 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0014 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.133 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
-
IC50: 0.009 mM
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
-
IC50: 0.0035 mM
1,1'-[[1,1'-biphenyl]-4,4'-diylbis(methylene)]bis[4-[(4-chlorophenyl)(methyl)amino]quinolin-1-ium]
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
1-(4-(4-[(3-aminophenoxy)methyl]phenethyl)benzyl)-4-(dimethylamino)pyridinium bromide
21.9% inhibition at 0.05 mM
1-(4-[4-[(3-hydroxyphenylamino)methyl]phenethyl]-benzyl)-4-(pyrrolidin-1-yl)pyridinium bromide
13.6% inhibition at 0.05 mM
1-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenethyl]benzyl)-4-pyrrolidinopyridinium bromide
0.1% inhibition at 0.01 mM, 24.8% inhibition at 0.05 mM
1-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenyl]benzyl)-4-(dimethylamino)pyridinium bromide
62.3% inhibition at 0.01 mM, 71.4% inhibition at 0.05 mM
1-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenethyl]benzyl)-4-(dimethylamino)pyridinium bromide
38.6% inhibition at 0.01 mM, 81% inhibition at 0.05 mM
1-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenethyl]benzyl)-4-pyrrolidinopyridinium bromide
28.6% inhibition at 0.01 mM, 46.9% inhibition at 0.05 mM
1-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]benzyl)-4-(dimethylamino)pyridinium bromide
37.6% inhibition at 0.01 mM, 51% inhibition at 0.05 mM
1-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]benzyl)-4-pyrrolidinopyridinium bromide
50.2% inhibition at 0.01 mM, 72.8% inhibition at 0.05 mM
1-([1,1'-biphenyl]-4-ylmethyl)-4-methyl-1,4-diazepane
-
1-([4'-[(3-aminophenoxy)methyl]biphenyl-4-yl]methyl)-4-(dimethylamino)pyridinium bromide
79.8% inhibition at 0.05 mM
1-([4'-[(3-aminophenoxy)methyl]biphenyl-4-yl]methyl)-4-(pyrrolidin-1-yl)pyridinium bromide
20.8% inhibition at 0.05 mM
1-([4'-[(3-hydroxyphenylamino)methyl]biphenyl-4-yl]-methyl)-4-(pyrrolidin-1-yl)-pyridinium bromide
28.2% inhibition at 0.05 mM
1-([4'-[(6-amino-9H-purin-9-yl)methyl][1,1'-biphenyl]-4-yl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
-
1-([4'-[(6-amino-9H-purin-9-yl)methyl][1,1'-biphenyl]-4-yl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-([4-[(6-amino-9H-purin-9-yl)methyl]phenyl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
-
1-([4-[(6-amino-9H-purin-9-yl)methyl]phenyl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-([4-[2-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)ethyl]phenyl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
-
1-([4-[2-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)ethyl]phenyl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-([4-[4-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)butyl]phenyl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
-
1-([4-[4-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)butyl]phenyl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
1-[(4'-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-4-(dimethylamino)pyridin-1-ium bromide
-
1-[(4'-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-[(4-[4-[4-([4-[(4-chlorophenyl)(methyl)amino]pyridin-1-ium-1-yl]methyl)phenyl]butyl]phenyl)methyl]-4-(dimethylamino)pyridin-1-ium
-
1-[(4-[4-[4-([4-[(4-chlorophenyl)(methyl)amino]pyridin-1-ium-1-yl]methyl)phenyl]butyl]phenyl)methyl]-4-(dimethylamino)pyridin-1-ium dibromide
-
1-[(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)methyl]-4-(dimethylamino)pyridin-1-ium bromide
-
1-[(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-[4'-[(6-amino-9H-purin-9-yl)methyl][1,1'-biphenyl]-4-yl]-4-(dimethylamino)pyridin-1-ium bromide
-
1-[4-(4-[4-[(3-aminophenoxy)methyl]phenyl]butyl)-benzyl]-4-(pyrrolidin-1-yl)pyridinium bromide
21.6% inhibition at 0.05 mM
1-[4-(4-[4-[(3-hydroxyphenylamino)methyl]phenyl]-butyl)benzyl]-4-(pyrrolidin-1-yl)pyridinium bromide
18% inhibition at 0.05 mM
1-[4-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenyl]butyl)benzyl]-4-(dimethylamino)pyridinium bromide
61.3% inhibition at 0.01 mM, 68.2% inhibition at 0.05 mM
1-[4-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenyl]butyl)benzyl]-4-pyrrolidinopyridinium bromide
22.6% inhibition at 0.01 mM, 59.9% inhibition at 0.05 mM
1-[4-(4-[4-[(6-amino-9H-purin-8-yl)methyl]phenyl]butyl)benzyl]-4-(dimethylamino)pyridinium bromide
-
-
1-[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)benzyl]-4-(dimethylamino)pyridinium bromide
66.7% inhibition at 0.01 mM, 89.7% inhibition at 0.05 mM
1-[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)benzyl]-4-pyrrolidinopyridinium bromide
36.9% inhibition at 0.01 mM, 41.9% inhibition at 0.05 mM
1-[4-[(3-aminophenoxy)methyl]benzyl]-4-(dimethylamino)pyridinium bromide
37.7% inhibition at 0.05 mM
1-[4-[(3-aminophenoxy)methyl]benzyl]-4-(pyrrolidin-1-yl)pyridinium bromide
12.9% inhibition at 0.05 mM
1-[4-[(3-hydroxyphenylamino)methyl]benzyl]-4-(pyrrolidin-1-yl)pyridinium bromide
41.3% inhibition at 0.05 mM
1-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine
analysis of the enzyme bound structure, PDB ID 5EQE
1-[4-[(6-amino-3H-purin-3-yl)methyl]benzyl]-4-(dimethylamino)pyridinium bromide
25% inhibition at 0.01 mM, 50.2% inhibition at 0.05 mM
1-[4-[(6-amino-9H-purin-9-yl)methyl]benzyl]-4-(dimethylamino)pyridinium bromide
46.7% inhibition at 0.01 mM, 54.1% inhibition at 0.05 mM
1-[4-[(6-amino-9H-purin-9-yl)methyl]benzyl]-4-pyrrolidinopyridinium bromide
27% inhibition at 0.05 mM
1-[[4-(2-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]ethyl)phenyl]methyl]-4-(dimethylamino)pyridin-1-ium bromide
-
1-[[4-(2-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]ethyl)phenyl]methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-[[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)phenyl]methyl]-4-(dimethylamino)pyridin-1-ium bromide
1-[[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)phenyl]methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
-
1-[[4-[4-[[4-(4-chloro-N-methylanilino)quinolin-1-ium-1-yl]methyl]phenyl]phenyl]methyl]-N-(4-chlorophenyl)-N-methylquinolin-1-ium-4-amine
i.e. TCD-717 or RSM-932A, strong inhibition of ChoKalpha, TCD-717 does not bind directly in the choline pocket but rather in a proximal location near the surface of the enzyme. Most notably, residues Tyr148, Ala176, Met177, Glu180, Phe200, Pro201, Trp248, Thr252, Tyr256, Glu332, Tyr333, Phe341, and Leu419 serve to orient and hold TCD-717 in place. Interaction of TCD-717 with ChoKalpha is driven by hydrophobic interactions across the N- and C-terminal domains. Binding of TCD-717 induces conformational changes compared to the unbound ChoKalpha structure. TCD-717 has completed phase I clinical trials
12,19-diaza-1,8-diazoniapentacyclo[18.2.2.23,6.28,11.214,17]triaconta-1(22),3,5,8,10,14,16,20,23,25,27,29-dodecaene dibromide
-
IC50: 0.0132 mM
12,21-diaza-1,8-diazoniapentacyclo[20.2.2.23,6.28,11.014,19]triaconta-1(24),3,5,8,10,14,16,18,22,25,27,29-dodecaene dibromide
-
IC50: 0.0021 mM
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
3-Trimethylammonio-1-propanol
-
-
4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol
-
-
-
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenethyl]benzyl)pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenyl]benzyl)pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenethyl]benzyl)pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenyl]benzyl)pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-[4-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenyl]butyl)benzyl]pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-[4-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenyl]butyl)benzyl]pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-[4-[(4-dimethylaminopyridinium-1-yl)methyl]benzyl]pyridinium dibromide
-
4-(4-chloro-N-methylanilino)-1-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]benzyl]pyridinium dibromide
-
4-(dimethylamino)-1-(4-(3-(4-(((3-hydroxyphenyl)amino)methyl)phenyl)propyl)benzyl)pyridin-1-ium bromide
12.9% inhibition at 0.05 mM
4-(dimethylamino)-1-(4-(4-(((3-hydroxyphenyl)amino)methyl)benzyl)benzyl)pyridin-1-ium bromide
39.5% inhibition at 0.05 mM
4-(dimethylamino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenethyl]benzyl)pyridinium dibromide
-
4-(dimethylamino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenyl]benzyl)pyridinium dibromide
-
4-(dimethylamino)-1-({4-[(3-hydroxyphenylamino)-methyl]biphenyl-4-yl}methyl)pyridinium bromide
66.2% inhibition at 0.05 mM
4-(dimethylamino)-1-[4-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenyl]butyl)benzyl]pyridinium dibromide
-
4-(dimethylamino)-1-[4-[(3-hydroxyphenylamino)-methyl]benzyl]pyridinium bromide
52.4% inhibition at 0.05 mM
4-(dimethylamino)-1-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]-benzyl]pyridinium dibromide
-
4-chloro-N-methylanilino
-
IC50: 0.0014 mM
4-[(4-chlorophenyl)(methyl)amino]-1-[(4'-[[4-(dimethylamino)phenyl]methyl][1,1'-biphenyl]-4-yl)methyl]pyridin-1-ium bromide
-
5'-dithio-bis-(2-nitrobenzoic acid)
-
modest inhibitory activity
5,10,11,16,17,22-hexahydro-6,9:18,21-diethenodibenzo[g,p][1,5,10,14]tetraazacyclooctadecine-6,21-diium dibromide
-
IC50: 0.0248 mM
5,5'-dithiobis(2-nitrobenzoic acid)
5-fluorouracil
-
Investigation of the effect of combining transient siRNA-chk transfection with the anticancer drug 5-fluorouracil on cell viability and proliferation. Choline kinase down-regulation with 5-fluorouracil treatment increased cell kill in cancer cells.
6-(trifluoromethyl)pyrimidin-4-amine
-
6-amino-3-([4-[4-(4-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl]phenyl)butyl]phenyl]methyl)-9H-purin-3-ium
-
6-amino-3-([4-[4-(4-[[4-(pyrrolidin-1-yl)pyridin-1-ium-1-yl]methyl]phenyl)butyl]phenyl]methyl)-9H-purin-3-ium
-
6-amino-3-[(4'-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-9H-purin-3-ium
6-amino-3-[(4-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl]phenyl)methyl]-9H-purin-3-ium
-
6-[(1-methyl-1,4-diazepan-6-yl)methyl]quinoline
-
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
7-chloro-1-(4-[2-[4-(7-chloro-5-pyrrolidin-1-ylquinolinium-1-yl)phenyl]ethyl]phenyl)-4-pyrrolidin-1-ylquinolinium
-
choline kinase inhibitor Mn58b
-
choline kinase inhibitor TCD828
-
-
-
Cytidine diphosphocholine
-
-
EDTA
about 10% residual activity at 5 mM
H-89
-
no activity on choline kinase at 5 mM ATP, decreasing the ATP concentration to 100 microM has no effect on choline kinase
hexadecyltrimethylammonium bromide
-
60% inhibition at 0.1 mM; HDTAB, structural resemblance to hexadecylphosphocholine, exhibits an antimalarial effect and inhibits choline kinase in a dose-dependent manner. For purified protein: 60% inhibition at 100 microM (in presence of 250 microM choline), 60% inhibition at 50 microM (in presence of 100 microM choline). HDTAB may compete with choline for the choline binding site of choline kinase and may offer competitive inhibition with respect to choline. The concentration of HDTAB required to inhibit Plasmodium falciparum growth by 62% was 10times lower than the concentration required to inhibit purified choline kinase by 60% in vitro
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
N,N,N-trimethyl-N-(5,5-diphenylpent-4-en-1-yl)ammonium iodide
-
-
N,N,N-trimethyl-N-(6,6-diphenylhex-5-en-1-yl)ammonium iodide
-
-
N-(3,5-dimethylphenyl)-2-[[5-(4-ethylphenyl)-1H-1,2,4-triazol-3-yl]sulfanyl]acetamide
CK37, identified through computational virtual screening, inhibits ChoKalpha activity both in enzymatic and in cellular assays, is able to suppress pCho production and tumor growth in vivo
N-iodomethyl-N,N-dimethyl-N-(4,4-diphenylbut-3-en-1-yl)ammonium iodide
-
-
N-iodomethyl-N,N-dimethyl-N-(5,5-diphenylpent-4-en-1-yl)ammonium iodide
-
-
N-iodomethyl-N,N-dimethyl-N-(6,6-diphenylhex-5-en-1-yl)ammonium iodide
-
-
N-iodomethylcholine iodide
-
-
N-Methyl-N,N-diisopropylethanolamine
-
-
N-Methyl-N-isopropylethanolamine
-
-
N-[2-bromocinnamyl(amino)ethyl]-5-isoquinoline sulfonamide
-
-
NaCl
-
8.7-35 mM: slight activation, 70 mM: inactivation
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
phosphocholine
-
40% and 66% inhibition at 2.5 mM and 10 mM, respectively
piperazine
-
modest inhibitory activity
purinyl-6-histamine
-
modest inhibitory activity
Quinacrine
-
indirect inhibitor
RSM932A
also called TCD-717
Triethanolammonio-1-choline
-
-
[4-(4-methyl-1,4-diazepan-1-yl)phenyl]methanol
-
(1-azabicyclo[2.2.2]octan-3-yl)bis(5-chlorothiophen-2-yl)methanol
-
(1-azabicyclo[2.2.2]octan-3-yl)bis(5-chlorothiophen-2-yl)methanol
precursor of (1S)-1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-[(oxan-4-yl)oxy]phenyl]-1-phenylpropan-1-ol, inhibits competitively against ATP, but not against choline
(1S)-1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-[(oxan-4-yl)oxy]phenyl]-1-phenylpropan-1-ol
-
(1S)-1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-[(oxan-4-yl)oxy]phenyl]-1-phenylpropan-1-ol
a structure-directed, selective ChoKalpha inhibitor. Treatment of HeLa cells and other cancer cells with the compound leads to a substantial reduction in the pCho level, and causes a reversible growth arrest but not cell death
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
-
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
-
1,1'-[butane-1,4-diylbis[(4,1-phenylene)methylene]]bis[4-(dimethylamino)pyridin-1-ium]
-
1,1'-[butane-1,4-diylbis[(4,1-phenylene)methylene]]bis[4-(dimethylamino)pyridin-1-ium]
a less toxic derivative of hemicholinium-3, it inhibits endogenous ChoKbeta activity and suppress breast cancer, colon cancer, and epidermoid carcinoma xenograft growth in vivo
1,1'-[butane-1,4-diylbis[(4,1-phenylene)methylene]]bis[4-(dimethylamino)pyridin-1-ium]
MN58b, mixed inhibition type with both choline and ATP
1,1'-[[1,1'-biphenyl]-4,4'-diylbis(methylene)]bis[4-[(4-chlorophenyl)(methyl)amino]quinolin-1-ium]
RSM-932A or TDC-717, a potential cancer therapeutic agent targeting choline metabolism, strong inhibition
1,1'-[[1,1'-biphenyl]-4,4'-diylbis(methylene)]bis[4-[(4-chlorophenyl)(methyl)amino]quinolin-1-ium]
RSM-932A, mixed inhibition type with choline, non-competitive with ATP
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
-
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
-
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
-
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
-
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
-
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
-
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
-
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
-
1-[[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)phenyl]methyl]-4-(dimethylamino)pyridin-1-ium bromide
-
1-[[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)phenyl]methyl]-4-(dimethylamino)pyridin-1-ium bromide
-
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
-
IC50: 0.0003 mM
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
-
IC50: 0.0003 mM, most potent inhibitor
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
-
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
-
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
-
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
-
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
-
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
-
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
-
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
-
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
-
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
-
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
6-amino-3-[(4'-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-9H-purin-3-ium
-
6-amino-3-[(4'-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-9H-purin-3-ium
-
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
-
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
-
Acetylcholine
-
-
adenosine
competitive with MgATP2-
adenosine
competitive with MgATP2-
ADP
-
-
ADP
-
50% inhibition at 0.32 mM, in a positive cooperative manner
AMP
-
-
ATP
-
at 4.9 mM and 8.0 mM 30% inhibition; optimum concentration: 3.2-4.0 mM
Ca2+
-
-
choline
-
-
Choline analogues
several compounds tested and found to be inhibitory
Choline analogues
several compounds tested and found to be inhibitory
choline kinase inhibitor Mn58b
-
-
-
choline kinase inhibitor Mn58b
-
-
ethanolamine
-
inhibition only at very high concentration, 100-150 mM
ethanolamine
-
no significant effect
ethanolamine
-
poor inhibitor
ethanolamine
-
weak competitive inhibitor
HC-3
-
HC-3
-
poor inhibition of 16% and 18% is observed at 50 microM and 150 microM, respectively, at both 100 and 250 microM choline
hemicholinium
-
-
hemicholinium-3
-
-
hemicholinium-3
-
weak inhibitor, IC50: 0.057 mM
hemicholinium-3
competitive inhibitor, the inhibitory effect of hemicholinium-3 is about 500times higher toward the ChoKalpha isoforms than ChoKbeta isoform; competitive inhibitor, the inhibitory effect of hemicholinium-3 is about 500times higher toward the ChoKalpha isoforms than ChoKbeta isoform
hemicholinium-3
HC-3, a substrate site inhibitor that bears structural homology to choline, which contributes to its toxicity
hemicholinium-3
-
poor inhibition of 16% and 18% at 0.050 mM and 0.15 mM, respectively, not significantly inhibited by hemicholinium-3 up to 0.025 mM
hemicholinium-3
HC-3, HC-3 competes with the Cho substrate by directly displacing it from the active site of hChoK. Hemocholinium-3 blocks cell division, reduces LTA production, distorts the cell wall, and inhibits sChoK activity
hemicholinium-3
HC-3, MIC is 5.4 mM
KF
-
methionine
-
-
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
-
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
-
MN58b
-
specific inhibitor, IC50: 0.0005-0.072 mM depending on cell type
MN58b
-
specific for choline kinase
MN58b
dysregulates the production of LTA, distorts the cell wall, and affects cell sensitivity to deoxycholate induced autolysis
N-ethylmaleimide
-
N-ethylmaleimide
-
modest inhibitory activity
phosphorylcholine
-
-
RSM-932A
-
RSM-932A
dysregulates the production of LTA, distorts the cell wall, and affects cell sensitivity to deoxycholate induced autolysis
serine
-
not
stearoyl-CoA
-
additional information
not inhibited by 1-[4-(4-[4-[(3-aminophenoxy)methyl]phenyl]butyl)-benzyl]-4-(dimethylamino)pyridinium bromide
-
additional information
small molecule inhibitors of choline kinase identified by fragment-based drug discovery (NMR fragment screening and competition experiments), quantification of protein-ligand affinities, overview
-
additional information
-
small molecule inhibitors of choline kinase identified by fragment-based drug discovery (NMR fragment screening and competition experiments), quantification of protein-ligand affinities, overview
-
additional information
choline kinase inhibition and docking studies of a series of 6-(benzylthio)-9H-purin-9-yl-pyridinium derivatives using native ChoK from the cytosol of Hep-G2 cells and recombinantly expressed ChoKalpha, overview
-
additional information
chemotherapeutic drug design has centered on stopping the catalytic activity of choline kinase and reducing the downstream metabolites it produces
-
additional information
-
chemotherapeutic drug design has centered on stopping the catalytic activity of choline kinase and reducing the downstream metabolites it produces
-
additional information
-
the lethality of the homozygous choline kinase alpha knock-out mice embryos indicates the indispensable role of CK-alphain early embryogenesis
-
additional information
-
not: neostigmine
-
additional information
-
not: p-chloromercuribenzoate, N-ethylmaleeimide
-
additional information
-
not: CTP, ethanolamine phosphate
-
additional information
-
-
-
additional information
repurposing of drugs known to inhibit the human isoform of ChoK (hChoK), is a promising strategy for blocking the growth of Streptococcus pneumoniae cells and inhibiting the activity of the Streptococcus pneumoniae isoform of ChoK (sChok), with downstream physiological effects on the cell wall
-
additional information
-
repurposing of drugs known to inhibit the human isoform of ChoK (hChoK), is a promising strategy for blocking the growth of Streptococcus pneumoniae cells and inhibiting the activity of the Streptococcus pneumoniae isoform of ChoK (sChok), with downstream physiological effects on the cell wall
-
additional information
docking of MN58b and RSM-932A onto sChoK, overview. MN58b and RSM-932A fit into the active site of sChoK in a differential manner. In enzymatic assays with Streptoccocus pneumoniae extracts MN58b is still an inhibitor, while RSM-932A becomes an agonist
-
additional information
-
docking of MN58b and RSM-932A onto sChoK, overview. MN58b and RSM-932A fit into the active site of sChoK in a differential manner. In enzymatic assays with Streptoccocus pneumoniae extracts MN58b is still an inhibitor, while RSM-932A becomes an agonist
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.94
dimethylethanolamine
-
in 100 mM Tris-HCl (pH 8.5), at 37°C
0.025
N,N-diethylethanolamine
0.4
N,N-Diisopropylethanolamine
0.208
N,N-Dimethylaminopropanol
0.022 - 0.085
N,N-dimethylethanolamine
0.118 - 3.7
N-Monomethylethanolamine
additional information
ethanolamine
0.0206
ATP
-
-
0.4
ATP
isoform ChoKalpha2 mutant F352L, pH and temperature not specified in the publication
0.4
ATP
wild type isoform ChoKalpha2, pH and temperature not specified in the publication
0.4
ATP
wild type isoform ChoKbeta, pH and temperature not specified in the publication
0.486
ATP
in 100 mM Tris-HCl pH 7.5, 100 mM KCl, 10 mM MgCl2, at 25°C
0.55
ATP
isoform ChoKalpha2 mutant F352A, pH and temperature not specified in the publication
0.58
ATP
mutant choline kinase beta S39D/S40D, at pH 7.5 and 30°C
0.65
ATP
isoform ChoKbeta mutant F352A, pH and temperature not specified in the publication
0.65
ATP
phosphorylated choline kinase beta, at pH 7.5 and 30°C
0.7
ATP
-
isozyme CKB-2, pH 10.0, 37°C
0.7
ATP
isoform ChoKbeta mutant F352L, pH and temperature not specified in the publication
0.76
ATP
wild type isoform ChoKalpha1, pH and temperature not specified in the publication
1
ATP
-
C252S mutant enzyme, pH 10, 37°C
1
ATP
-
N308Q mutant enzyme, pH 10, 37°C
1.2
ATP
-
N354A mutant enzyme, pH 10, 37°C
1.3
ATP
-
D255D mutant enzyme, pH 10, 37°C
1.5
ATP
-
N308D mutant enzyme, pH 10, 37°C
1.7
ATP
-
E134A mutant enzyme, pH 10, 37°C
1.7
ATP
-
N87A mutant enzyme, pH 10, 37°C
1.7
ATP
-
wild type enzyme including His-tag, pH 10, 37°C
1.9
ATP
-
H253A mutant enzyme, pH 10, 37°C
1.9
ATP
-
S85T mutant enzyme, pH 10, 37°C
2
ATP
-
N308A mutant enzyme, pH 10, 37°C
2.2
ATP
-
E125D mutant enzyme, pH 10, 37°C
2.2
ATP
-
R149A mutant enzyme, pH 10, 37°C
2.2
ATP
-
W387A mutant enzyme, pH 10, 37°C
2.3
ATP
-
R149K mutant enzyme, pH 10, 37°C
2.4
ATP
-
isozyme CKA-2, pH 10.0, 37°C
2.4
ATP
-
wild type enzyme, pH 10, 37°C
2.5
ATP
-
S86A mutant enzyme, pH 10, 37°C
2.5
ATP
-
in 100 mM Tris/HCl, 6 mM MgCl2, 5 mM ATP, pH 8.8, at 37°C
3.1
ATP
-
N260A mutant enzyme, pH 10, 37°C
3.2
ATP
-
E125A mutant enzyme, pH 10, 37°C
4.2
ATP
-
E125Q mutant enzyme, pH 10, 37°C
4.5
ATP
-
E151A mutant enzyme, pH 10, 37°C
5.4
ATP
-
E303A mutant enzyme, pH 10, 37°C
6.9
ATP
-
E303D mutant enzyme, pH 10, 37°C
7
ATP
-
R111A mutant enzyme, pH 10, 37°C
8.8
ATP
-
E303Q mutant enzyme, pH 10, 37°C
45
ATP
-
E320A mutant enzyme, pH 10, 37°C
0.444
beta-Methylcholine
-
30°C
0.444
beta-Methylcholine
-
30°C, pH 8.0
0.002
choline
-
dimer
0.013
choline
-
liver enzyme
0.013
choline
-
pH 8.5, 37°C
0.014
choline
-
brain enzyme
0.021
choline
isoform ChoKalpha2 mutant F352L, pH and temperature not specified in the publication
0.032
choline
-
isozyme CK-beta
0.033
choline
wild type isoform ChoKbeta, pH and temperature not specified in the publication
0.041
choline
isoform ChoKbeta mutant F352L, pH and temperature not specified in the publication
0.055
choline
-
isozyme CK-alpha1/beta
0.07
choline
in 100 mM Tris-HCl buffer (pH 7.5) containing 100 mM KCl, 10 mM MgCl2, 0.5 mM phosphoenolpyruvate, 0.25 mM NADH, 4 units pyruvate kinase, and 5 units lactate dehydrogenase
0.083
choline
-
isozyme CK-alpha
0.086
choline
wild type isoform ChoKalpha2, pH and temperature not specified in the publication
0.089
choline
at pH 9.0 and 37°C
0.1
choline
-
kidney enzyme
0.102
choline
isoform ChoKbeta mutant F352A, pH and temperature not specified in the publication
0.107
choline
isoform ChoKalpha2 mutant F352A, pH and temperature not specified in the publication
0.13
choline
recombinant enzyme, pH 8.0, 25°C
0.1353
choline
recombinant protein
0.145
choline
-
in 100 mM Tris/HCl, 6 mM MgCl2, 5 mM ATP, pH 8.8, at 37°C
0.15
choline
at pH 8.0 and 37°C
0.157
choline
-
N-terminal truncated enzyme version of CK-beta
0.18
choline
wild type isoform ChoKalpha1, pH and temperature not specified in the publication
0.188
choline
in 100 mM Tris-HCl pH 7.5, 100 mM KCl, 10 mM MgCl2, at 25°C
0.27
choline
-
pH 9.5, 30°C
0.4
choline
-
N260A mutant enzyme, pH 10, 37°C
0.42
choline
phosphorylated choline kinase beta, at pH 7.5 and 30°C
0.46
choline
mutant choline kinase beta S39D/S40D, at pH 7.5 and 30°C
0.7
choline
-
R149A mutant enzyme, pH 10, 37°C
0.7
choline
-
S85T mutant enzyme, pH 10, 37°C
0.77
choline
-
in 100 mM Tris-HCl (pH 8.5), at 37°C
0.8
choline
-
E125D mutant enzyme, pH 10, 37°C
0.8
choline
-
N308Q mutant enzyme, pH 10, 37°C
1
choline
-
C252S mutant enzyme, pH 10, 37°C
1
choline
-
N308D mutant enzyme, pH 10, 37°C
1
choline
-
N354A mutant enzyme, pH 10, 37°C
1
choline
-
wild type enzyme including His-tag, pH 10, 37°C
1.1
choline
-
E125A mutant enzyme, pH 10, 37°C
1.2
choline
-
R149K mutant enzyme, pH 10, 37°C
1.2
choline
-
W387A mutant enzyme, pH 10, 37°C
1.5
choline
-
N308A mutant enzyme, pH 10, 37°C
1.6
choline
-
isozyme CKA-2, pH 10.0, 37°C
1.6
choline
-
E125Q mutant enzyme, pH 10, 37°C
1.6
choline
-
H253A mutant enzyme, pH 10, 37°C
1.6
choline
-
wild type enzyme, pH 10, 37°C
1.7
choline
-
R111A mutant enzyme, pH 10, 37°C
1.8
choline
-
E134A mutant enzyme, pH 10, 37°C
1.8
choline
-
N87A mutant enzyme, pH 10, 37°C
2.2
choline
-
E151A mutant enzyme, pH 10, 37°C
3
choline
-
E320A mutant enzyme, pH 10, 37°C
3.4
choline
-
E303Q mutant enzyme, pH 10, 37°C
3.6
choline
-
E303D mutant enzyme, pH 10, 37°C
5
choline
-
S86A mutant enzyme, pH 10, 37°C
5.4
choline
-
D255D mutant enzyme, pH 10, 37°C
10
choline
-
E303A mutant enzyme, pH 10, 37°C
13
choline
-
isozyme CKB-2, pH 10.0, 37°C
0.787
ethanolamine
-
30°C
0.787
ethanolamine
-
30°C, pH 8.0
1.2
ethanolamine
-
pH 8.5, 37°C
1.2
ethanolamine
-
30°C, pH 8.0
5
ethanolamine
-
in 100 mM Tris/HCl, 6 mM MgCl2, 5 mM ATP, pH 8.8, at 37°C
8.1
ethanolamine
-
pH 9.0
75
ethanolamine
at pH 9.0 and 37°C
0.025
N,N-diethylethanolamine
-
30°C, pH 8.0
0.025
N,N-diethylethanolamine
-
pH 9.6, 37°C
0.4
N,N-Diisopropylethanolamine
-
30°C
0.4
N,N-Diisopropylethanolamine
-
30°C, pH 8.0
0.208
N,N-Dimethylaminopropanol
-
30°C
0.208
N,N-Dimethylaminopropanol
-
30°C, pH 8.0
0.022
N,N-dimethylethanolamine
-
30°C
0.022
N,N-dimethylethanolamine
-
30°C, pH 8.0
0.085
N,N-dimethylethanolamine
-
pH 9.0
0.118
N-Monomethylethanolamine
-
30°C
0.118
N-Monomethylethanolamine
-
30°C, pH 8.0
3.7
N-Monomethylethanolamine
-
-
3.7
N-Monomethylethanolamine
-
cosubstrate ATP
additional information
ethanolamine
above 500 mM
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
steady-state kinetics
-
additional information
additional information
steady-state kinetics
-
additional information
additional information
-
steady-state kinetics
-
additional information
additional information
-
Km of MgATP2-: 10 mM, in presence of equimolar amounts of ATP and Mg2+, 1.5 mM, in 2.5-fold higher concentration of Mg2+ than ATP
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00002
(1S)-1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-[(oxan-4-yl)oxy]phenyl]-1-phenylpropan-1-ol
Homo sapiens
pH 7.0, 25°C, recombinant enzyme
0.000251
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
0.00951
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(3-hydroxyquinuclidinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00163
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)pyridinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00327
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00202
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)-7-chloroquinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00166
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(azepan-1-yl)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.001
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00685
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(methyl(phenyl)amino)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00956
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(pyrrolidin-1-yl)pyridinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.01622
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-((4-chlorophenyl)(methyl)amino)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00279
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(methyl(phenyl)amino)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.00092
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(7-chloro-4-(pyrrolidin-1-yl)quinolinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.03754
1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(quinuclidinium) bromide
Homo sapiens
at pH 8.5 and 37°C
0.0528
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0528 mM
0.0842
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0842 mM
0.0084
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0084 mM
0.0072
1,1'-(benzene-1,3-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0072 mM
0.0375
1,1'-(benzene-1,3-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
Homo sapiens
-
IC50: 0.0375 mM
0.0377
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0377 mM
0.024
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.024 mM
0.0097
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0097 mM
0.0029
1,1'-(benzene-1,4-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0029 mM
0.015
1,1'-(benzene-1,4-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
Homo sapiens
-
IC50: 0.015 mM
0.0119
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-amino-3-methylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0119 mM
0.0206
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-amino-7-chloroquinolinium) dibromide
Homo sapiens
-
IC50: 0.0206 mM
0.0012
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-aminoquinolinium) dibromide
Homo sapiens
-
IC50: 0.0012 mM
0.0005
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-azepan-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0005 mM
0.0019
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0019 mM
0.0058
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0058 mM
0.0026
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0026 mM
0.0015
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0015 mM
0.0021
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.0021 mM
0.147
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
Homo sapiens
-
IC50: 0.147 mM
0.0012
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0012 mM
0.0057
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.0057 mM
0.0044
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0044 mM
0.0013
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-(phenylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0013 mM
0.00043
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
Homo sapiens
-
IC50: 0.00043 mM
0.0004
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0004 mM
0.0568
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0568 mM
0.0096
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0096 mM
0.0031
1,1'-(biphenyl-3,3'-diyldimethanediyl)bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0031 mM
0.2
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-amino-3-methylquinolinium) dibromide
Homo sapiens
-
IC50: above 0.2 mM
0.0633
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-amino-7-chloroquinolinium) dibromide
Homo sapiens
-
IC50: 0.0633 mM
0.0811
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-aminoquinolinium) dibromide
Homo sapiens
-
IC50: 0.0811 mM
0.0022
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-azepan-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0022 mM
0.0088
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-piperidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0088 mM
0.0111
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-pyrrolidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.0111 mM
0.0034
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0034 mM
0.0018
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0018 mM
0.002
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.002 mM
0.0461
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0461 mM
0.0198
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0198 mM
0.0114
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.0114 mM
0.0397
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0397 mM
0.0178
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-(phenylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0178 mM
0.0043
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-[(phenylamino)methyl]pyridinium] dibromide
Homo sapiens
-
IC50: 0.0043 mM
0.003
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.003 mM
0.0961
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0961 mM
0.0206
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0206 mM
0.0114
1,1'-(biphenyl-4,4'-diyldimethanediyl)bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0114 mM
0.08
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis(4-aminoquinolinium)
Homo sapiens
-
0.0006
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis(4-azepan-1-ylquinolinium)
Homo sapiens
-
0.0102
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0023
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-(phenylamino)quinolinium]
Homo sapiens
-
0.0048
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.0014
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.0575
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
Homo sapiens
-
0.133
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.009
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0057
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.0035
1,1'-(ethane-1,2-diyldibenzene-4,1-diyl)bis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.01109
1,1'-biphenyl-3,3'-diylbis(4-amino-3-methylquinolinium)
Homo sapiens
-
0.0206
1,1'-biphenyl-3,3'-diylbis(4-amino-7-chloroquinolinium)
Homo sapiens
-
0.0012
1,1'-biphenyl-3,3'-diylbis(4-aminoquinolinium)
Homo sapiens
-
0.0005
1,1'-biphenyl-3,3'-diylbis(4-azepan-1-ylquinolinium)
Homo sapiens
-
0.0012
1,1'-biphenyl-3,3'-diylbis(7-chloro-4-pyrrolidin-1-ylquinolinium)
Homo sapiens
-
0.0044
1,1'-biphenyl-3,3'-diylbis[4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0013
1,1'-biphenyl-3,3'-diylbis[4-(phenylamino)quinolinium]
Homo sapiens
-
0.0021
1,1'-biphenyl-3,3'-diylbis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.0004
1,1'-biphenyl-3,3'-diylbis[4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.147
1,1'-biphenyl-3,3'-diylbis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
Homo sapiens
-
0.0568
1,1'-biphenyl-3,3'-diylbis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.0096
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0057
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.0031
1,1'-biphenyl-3,3'-diylbis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.0633
1,1'-biphenyl-4,4'-diylbis(4-amino-7-chloroquinolinium)
Homo sapiens
-
0.0811
1,1'-biphenyl-4,4'-diylbis(4-aminoquinolinium)
Homo sapiens
-
0.0022
1,1'-biphenyl-4,4'-diylbis(4-azepan-1-ylquinolinium)
Homo sapiens
-
0.0198
1,1'-biphenyl-4,4'-diylbis(7-chloro-4-pyrrolidin-1-ylquinolinium)
Homo sapiens
-
0.0397
1,1'-biphenyl-4,4'-diylbis[4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0178
1,1'-biphenyl-4,4'-diylbis[4-(phenylamino)quinolinium]
Homo sapiens
-
0.002
1,1'-biphenyl-4,4'-diylbis[4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.003
1,1'-biphenyl-4,4'-diylbis[4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.0461
1,1'-biphenyl-4,4'-diylbis[7-amino-4-[(4-chlorophenyl)(methyl)amino]-8-methylquinolinium]
Homo sapiens
-
0.0961
1,1'-biphenyl-4,4'-diylbis[7-amino-8-methyl-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.0206
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-(dimethylamino)quinolinium]
Homo sapiens
-
0.0114
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-[(4-chlorophenyl)(methyl)amino]quinolinium]
Homo sapiens
-
0.0114
1,1'-biphenyl-4,4'-diylbis[7-chloro-4-[methyl(phenyl)amino]quinolinium]
Homo sapiens
-
0.098
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-piperidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: 0.098 mM
0.1
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-pyrrolidin-1-ylpyridinium) dibromide
Homo sapiens
-
IC50: above 0.1 mM
0.0482 - 0.1
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
0.1
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis[4-[(phenylamino)methyl]pyridinium] dibromide
Homo sapiens
-
IC50: above 0.1 mM
0.2
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-amino-7-chloroquinolinium) dibromide
Homo sapiens
-
IC50: above 0.2 mM
0.08
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-aminoquinolinium) dibromide
Homo sapiens
-
IC50: 0.08 mM
0.006
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-azepan-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.006 mM
0.0048
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.0048 mM
0.0575
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-amino-4-[[(4-chlorophenyl)amino]methyl]-8-methylquinolinium) dibromide
Homo sapiens
-
IC50: 0.0575 mM
0.001
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-chloro-4-pyrrolidin-1-ylquinolinium) dibromide
Homo sapiens
-
IC50: 0.001 mM
0.0057
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis(7-chloro-4-[[(4-chlorophenyl)amino]methyl]quinolinium) dibromide
Homo sapiens
-
IC50: 0.0057 mM
0.0102
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0102 mM
0.0023
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-(phenylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.0023 mM
0.0014
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0014 mM
0.133
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-amino-8-methyl-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.133 mM
0.009
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-chloro-4-(dimethylamino)quinolinium] dibromide
Homo sapiens
-
IC50: 0.009 mM
0.0035
1,1'-[ethane-1,2-diylbis(benzene-4,1-diylmethanediyl)]bis[7-chloro-4-[(phenylamino)methyl]quinolinium] dibromide
Homo sapiens
-
IC50: 0.0035 mM
0.00143
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
0.00621
1-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenyl]benzyl)-4-(dimethylamino)pyridinium bromide
Homo sapiens
in 100 mM Tris (pH 8.5), 10 mM MgCl2, at 37°C
0.0015
1-([1,1'-biphenyl]-4-ylmethyl)-4-methyl-1,4-diazepane
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.00232
1-([4-[2-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)ethyl]phenyl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.01836
1-([4-[2-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)ethyl]phenyl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.01883
1-([4-[4-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)butyl]phenyl]methyl)-4-(dimethylamino)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.05
1-([4-[4-(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)butyl]phenyl]methyl)-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
Homo sapiens
above, pH and temperature not specified in the publication, recombinant ChoKalpha
0.0013 - 0.0015
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
0.0026
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
0.0026
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
0.0015
1-[(4'-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-4-(dimethylamino)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.05
1-[(4'-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl][1,1'-biphenyl]-4-yl)methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
Homo sapiens
above, pH and temperature not specified in the publication, recombinant ChoKalpha
0.0004
1-[(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)methyl]-4-(dimethylamino)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.00791
1-[(4-[[6-(benzylsulfanyl)-9H-purin-9-yl]methyl]phenyl)methyl]-4-(pyrrolidin-1-yl)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.0389
1-[4-(4-[4-[(6-amino-3H-purin-3-yl)methyl]phenyl]butyl)benzyl]-4-(dimethylamino)pyridinium bromide
Homo sapiens
in 100 mM Tris (pH 8.5), 10 mM MgCl2, at 37°C
0.0107
1-[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)benzyl]-4-(dimethylamino)pyridinium bromide
Homo sapiens
in 100 mM Tris (pH 8.5), 10 mM MgCl2, at 37°C
0.087
1-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0107
1-[[4-(4-[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]butyl)phenyl]methyl]-4-(dimethylamino)pyridin-1-ium bromide
Homo sapiens
pH and temperature not specified in the publication, recombinant ChoKalpha
0.00052
1-[[4-[4-[[4-(4-chloro-N-methylanilino)quinolin-1-ium-1-yl]methyl]phenyl]phenyl]methyl]-N-(4-chlorophenyl)-N-methylquinolin-1-ium-4-amine
Homo sapiens
wild-type enzyme ChoKalpha, pH 7.5, 37°C
0.0132
12,19-diaza-1,8-diazoniapentacyclo[18.2.2.23,6.28,11.214,17]triaconta-1(22),3,5,8,10,14,16,20,23,25,27,29-dodecaene dibromide
Homo sapiens
-
IC50: 0.0132 mM
0.0021
12,21-diaza-1,8-diazoniapentacyclo[20.2.2.23,6.28,11.014,19]triaconta-1(24),3,5,8,10,14,16,18,22,25,27,29-dodecaene dibromide
Homo sapiens
-
IC50: 0.0021 mM
0.0003
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
0.000085
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
3.2
2-amino-1-butanol
Plasmodium falciparum 3D7
endogenous enzyme
0.000233
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
0.000165
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
0.000255
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
0.000268
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
0.000457
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
0.000066
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
0.0007
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenethyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0015
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0025
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenethyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0022
4-(4-chloro-N-methylanilino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0012
4-(4-chloro-N-methylanilino)-1-[4-(4-[4-[(4-dimethylaminopyridinium-1-yl)methyl]phenyl]butyl)benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0015
4-(4-chloro-N-methylanilino)-1-[4-(4-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]phenyl]butyl)benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0009
4-(4-chloro-N-methylanilino)-1-[4-[(4-dimethylaminopyridinium-1-yl)methyl]benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0006
4-(4-chloro-N-methylanilino)-1-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0012
4-(dimethylamino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenethyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0008
4-(dimethylamino)-1-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenyl]benzyl)pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0009
4-(dimethylamino)-1-[4-(4-[4-[(4-pyrrolidinopyridinium-1-yl)-methyl]phenyl]butyl)benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.008
4-(dimethylamino)-1-[4-[(4-pyrrolidinopyridinium-1-yl)methyl]-benzyl]pyridinium dibromide
Homo sapiens
at pH 8.5 and 37°C
0.0014
4-chloro-N-methylanilino
Homo sapiens
-
IC50: 0.0014 mM
0.0248
5,10,11,16,17,22-hexahydro-6,9:18,21-diethenodibenzo[g,p][1,5,10,14]tetraazacyclooctadecine-6,21-diium dibromide
Homo sapiens
-
IC50: 0.0248 mM
0.0172
6-[(1-methyl-1,4-diazepan-6-yl)methyl]quinoline
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0015 - 0.0039
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
0.001
7-chloro-1-(4-[2-[4-(7-chloro-5-pyrrolidin-1-ylquinolinium-1-yl)phenyl]ethyl]phenyl)-4-pyrrolidin-1-ylquinolinium
Homo sapiens
-
0.005 - 0.1075
choline kinase inhibitor Mn58b
-
0.057 - 2.7
hemicholinium-3
0.00495
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
0.0005
RSM-932A
Streptococcus pneumoniae
pH and temperature not specified in the publication
0.00192
RSM932A
Homo sapiens
at pH 8.5 and 37°C
0.00047
V-11-023907
Homo sapiens
in 100 mM Tris-HCl pH 7.5, 100 mM KCl, 10 mM MgCl2, at 25°C
2
[4-(4-methyl-1,4-diazepan-1-yl)phenyl]methanol
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
additional information
additional information
Homo sapiens
IC50 values for inhibitors with HepG2 cell and the cytosolic fraction of HepG2 cells, overview
-
0.000251
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000251
(4-methyl-1,4-diazepan-1-yl)(4'-((4-methyl-1,4-diazepan-1-yl)-methyl)-[1,1'-biphenyl]-4-yl)methanone
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0482
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: 0.0482 mM
0.1
1,1'-[(1S,2S)-cyclopropane-1,2-diyldiethane-2,1-diyl]bis(4-[[(3,5-dichlorophenyl)amino]methyl]pyridinium) dibromide
Homo sapiens
-
IC50: above 0.1 mM
0.00143
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.00143
1-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-1,4-diazepane
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0013
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0013
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0015
1-methyl-4-((4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-methyl)-1,4-diazepane
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0026
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0026
1-methyl-4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)-1,4-diazepane
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0026
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.0026
1-methyl-4-(naphthalen-2-ylmethyl)-1,4-diazepane
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0003
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
Homo sapiens
-
IC50: 0.0003 mM
0.0003
14,21-diaza-1,10-diazoniapentacyclo[20.2.2.210,13.216,19.03,8]triaconta-1(24),3,5,7,10,12,16,18,22,25,27,29-dodecaene dibromide
Homo sapiens
-
IC50: 0.0003 mM, most potent inhibitor
0.000085
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000085
2'-fluoro-4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000233
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000233
4,4'-((2,3-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000165
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000165
4,4'-((2-fluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000255
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000255
4,4'-((3,5-difluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis-(1-methyl-1,4-diazepane)
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000268
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000268
4,4'-((3-chloro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(1-methyl-1,4-diazepane)
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000457
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000457
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-1,1'-biphenyl
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.000066
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.000066
4,4'-bis((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0015
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0039
7-((4-methyl-1,4-diazepan-1-yl)methyl)quinolone
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.005
choline kinase inhibitor Mn58b
Homo sapiens
-
-
0.1075
choline kinase inhibitor Mn58b
Homo sapiens
-
-
0.057
hemicholinium-3
Homo sapiens
-
weak inhibitor, IC50: 0.057 mM
0.22
hemicholinium-3
Plasmodium falciparum 3D7
endogenous enzyme
0.58
hemicholinium-3
Plasmodium falciparum 3D7
recombinant enzyme
2.7
hemicholinium-3
Streptococcus pneumoniae
pH and temperature not specified in the publication
2.7
hemicholinium-3
Streptococcus pneumoniae
recombinant enzyme, pH 8.0, 25°C
0.00495
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
Homo sapiens
pH 7.5, 25°C, recombinant enzyme
0.00495
methyl 4'-((4-methyl-1,4-diazepan-1-yl)methyl)-[1,1'-biphenyl]-4-carboxylate
Homo sapiens
at pH 7.0, temperature not specified in the publication
0.0001
MN58b
Homo sapiens
-
H510 cell, 144 h
0.00027
MN58b
Homo sapiens
-
H82 cell, 144 h
0.0004
MN58b
Homo sapiens
-
H510 cell, 72 h
0.0005 - 0.072
MN58b
Homo sapiens
-
specific inhibitor, IC50: 0.0005-0.072 mM depending on cell type
0.00078
MN58b
Homo sapiens
at pH 8.5 and 37°C
0.0008
MN58b
Homo sapiens
-
H82 cell, 72 h
0.0009
MN58b
Homo sapiens
-
H1299 cell, 144 h
0.0011
MN58b
Homo sapiens
-
H460 cell, 144 h
0.0011
MN58b
Homo sapiens
-
H510 cell, 48 h
0.0019
MN58b
Homo sapiens
-
H82 cell, 48 h
0.0026
MN58b
Homo sapiens
-
H460 cell, 72 h
0.0027
MN58b
Homo sapiens
-
H1299 cell, 72 h
0.0034
MN58b
Homo sapiens
-
primary HMEC cell, 144 h
0.0042
MN58b
Homo sapiens
-
primary BEC cell, 144 h
0.00703
MN58b
Homo sapiens
-
H460 cell, 48 h
0.0103
MN58b
Homo sapiens
-
H1299 cell, 48 h
0.0183
MN58b
Homo sapiens
-
primary BEC cell, 72 h
0.0209
MN58b
Homo sapiens
-
primary HMEC cell, 72 h
0.0405
MN58b
Homo sapiens
-
primary BEC cell, 48 h
0.0447
MN58b
Homo sapiens
-
primary HMEC cell, 48 h
0.197
MN58b
Streptococcus pneumoniae
pH and temperature not specified in the publication
0.52
SAR97276
Plasmodium falciparum 3D7
endogenous enzyme
1.12
SAR97276
Plasmodium falciparum 3D7
recombinant enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
choline kinase exists as two isoforms, alpha (ChoKalpha1 and 2) and beta. The alpha and beta isoforms are structurally similar and have sequence identity of 59%. The alpha isoform has a longer N-terminal sequence that shares no identity with the beta isoform, it also has a splice variant where residues 155-172 are missing (denoted ChoKalpha2), the unspliced variant, ChoKalpha1, has 457 residues
evolution
in Arabidopsis thaliana, the CEK family consists of four isoforms. Isozymes in this family may phosphorylate choline (Cho kinase, EC 2.7.1.32) or ethanolamine (Etn kinase, EC 2.7.1.82) in the presence of ATP and magnesium ions, producing phosphocholine (PCho) or phosphoethanolamine (PEtn), respectively
evolution
the mammalian choline kinase family is encoded by two distinct genes, ChoKalpha and ChoKbeta, resulting in three different isoforms, namely, ChoKalpha1, ChoKalpha2, and ChoKbeta. ChoKalpha1 (457 amino acids) and ChoKalpha2 (439 amino acids) are derived from a single gene (ChoKalpha) by alternative splicing
evolution
-
in Arabidopsis thaliana, the CEK family consists of four isoforms. Isozymes in this family may phosphorylate choline (Cho kinase, EC 2.7.1.32) or ethanolamine (Etn kinase, EC 2.7.1.82) in the presence of ATP and magnesium ions, producing phosphocholine (PCho) or phosphoethanolamine (PEtn), respectively
-
malfunction
-
deletion of choline kinase gene Chkb results in neonatal forelimb bone deformity and hindlimb muscular dystrophy. The virtual elimination of all choline kinase activity in hindlimb muscle of Chkb-/- mice is not compensated by isoform CKalpha activity and muscular dystrophy develops. In contrast, in forelimb muscles of these mice, the 50% of total choline kinase activity remaining (due to isoform CKalpha), and the increased activity of CTP:phosphocholine cytidylyltransferase, ensure that the amount of phosphocholine is not reduced so that only minimal signs of muscular dystrophy develop as the mice age
malfunction
enzyme knockdown in MCF-7 and MCF-10A cells reduces epidermal growth factor-dependent cell proliferation
malfunction
-
silencing of CKalpha leads to a lethal phenotype with aberrant mitotic arrest and subsequent apoptosis, and is rescued by simultaneous knockdown of CKalpha and CKbeta isoforms
malfunction
-
the parasite compensates for the loss of full-length enzyme by two potential 53- and 44 kDa isoforms
malfunction
the silencing of choline kinase alpha reduces cell proliferation. Moreover, pharmacological inhibition of choline kinase activity impairs the mineralization capacity of MG-63 cells
malfunction
choline kinase inhibitor MN58b sensitizes Streptococcus pneumoniae cells to autolysis while inhibitor RSM-932A does not. MN58b and RSM-932A do not provoke or prevent autolysis. Effect of the drugs on LTA production, overview. MN58b but not RSM-932A causes deformation of the Streptococcus pneumoniae cell wall
malfunction
increased cellular pCho levels lead to increased cellular proliferation. Other downstream products of the Kennedy pathway include phosphatidylcholine, which stimulates growth factor-induced DNA synthesis, and glycerophosphocholine, which is incorporated into cell membranes and is necessary for cell proliferation
malfunction
selective inhibition of the enzyme and the Kennedy pathway leads to the parasite arrest and eradication
malfunction
the LTA pathway is disrupted via inhibition of sChoK with strong downstream physiological consequences affecting cell growth
malfunction
under tunicamycin (Tm) treatment, seedling growth is retarded in mutants cek2-1, cek3-1 and wild-type, mutant cek1-1 exhibits severe growth defects. The expression of the other CEK isoforms (CEK2, CEK3, and CEK4) does not change significantly in either wild-type or cek1-1 before and after Tm treatment
malfunction
upon tunicamycin-induced ER stress, a null mutant of CEK1 shows hypersensitive phenotype in seedlings, albeit with no enhanced choline kinase activity. Analysis of the hypersensitive phenotype of a cek1 mutant under tunicamycin-induced endoplasmic reticulum stress. Under tunicamycin (Tm) treatment, seedling growth is retarded in mutants cek2-1, cek3-1 and wild-type, mutant cek1-1 exhibits severe growth defects. The expression of the other CEK isoforms (CEK2, CEK3, and CEK4) does not change significantly in either wild-type or cek1-1 before and after Tm treatment
malfunction
-
under tunicamycin (Tm) treatment, seedling growth is retarded in mutants cek2-1, cek3-1 and wild-type, mutant cek1-1 exhibits severe growth defects. The expression of the other CEK isoforms (CEK2, CEK3, and CEK4) does not change significantly in either wild-type or cek1-1 before and after Tm treatment
-
malfunction
-
upon tunicamycin-induced ER stress, a null mutant of CEK1 shows hypersensitive phenotype in seedlings, albeit with no enhanced choline kinase activity. Analysis of the hypersensitive phenotype of a cek1 mutant under tunicamycin-induced endoplasmic reticulum stress. Under tunicamycin (Tm) treatment, seedling growth is retarded in mutants cek2-1, cek3-1 and wild-type, mutant cek1-1 exhibits severe growth defects. The expression of the other CEK isoforms (CEK2, CEK3, and CEK4) does not change significantly in either wild-type or cek1-1 before and after Tm treatment
-
malfunction
-
the LTA pathway is disrupted via inhibition of sChoK with strong downstream physiological consequences affecting cell growth
-
malfunction
-
choline kinase inhibitor MN58b sensitizes Streptococcus pneumoniae cells to autolysis while inhibitor RSM-932A does not. MN58b and RSM-932A do not provoke or prevent autolysis. Effect of the drugs on LTA production, overview. MN58b but not RSM-932A causes deformation of the Streptococcus pneumoniae cell wall
-
metabolism
the sChoK enzyme is an element of the pathway that mediates the decoration of teichoic acids with PCho via the intermediary CDP-choline
metabolism
the sChoK enzyme is an element of the pathway that mediates the production of teichoic acids via the intermediary CDP-choline. The elements of this pathway are expressed via thelic gene locus. The LicB gene expresses a Cho transporter, which collects Cho from the external environment. LicA codes for sChoK which phosphorylates Cho into PCho. LicC is a gene coding for cytidylyl transferase which converts PCho into CDP-choline
metabolism
within the Kennedy pathway, the Plasmodium falciparum choline kinase (PfChoK) has a central role in the biosynthesis of phosphatidylcholine. Plasmodium falciparum plasma membrane is mainly composed by phosphatidylcholine (PC) and phosphatidylethanolamine (PE), which represent 40-50% and 35-40% of the total phospholipid content, respectively
metabolism
-
the sChoK enzyme is an element of the pathway that mediates the production of teichoic acids via the intermediary CDP-choline. The elements of this pathway are expressed via thelic gene locus. The LicB gene expresses a Cho transporter, which collects Cho from the external environment. LicA codes for sChoK which phosphorylates Cho into PCho. LicC is a gene coding for cytidylyl transferase which converts PCho into CDP-choline
-
metabolism
-
the sChoK enzyme is an element of the pathway that mediates the decoration of teichoic acids with PCho via the intermediary CDP-choline
-
physiological function
-
levels of CKalpa and CKbeta play an essential role in progression through mitosis, but not in resting cells or during DNA replication
physiological function
the enzyme is required for maximum epidermal growth factor-dependent cell growth in mammary epithelium-derived cell lines MCF-7 and MCF-10A
physiological function
choline kinase and its product phosphocholine are required for the normal growth and mineralization of MG-63 cells
physiological function
choline kinase beta, in concert with choline kinase alpha, and depending on its phosphorylation status, plays a critical role in carcinogenesis
physiological function
choline is not a nutritional requirement, but this pathogen does acquire choline from environmental sources and host cells, and produces phosphocholine which, in turn, are used to decorate lipopolysaccharides (LPS). Modified LPS molecules mediate pathogen-host cell interactions allowing the pathogen to evade the host immune system. Choline kinase (ChoK) plays a role in the growth and pathogenesis for humans of Gram-negative bacterium Haemophilus influenzae
physiological function
choline kinase (ChoK) is a cytosolic enzyme that catalyzes the MgATP-dependent phosphorylation of choline to phosphocholine (pCho) as the first step in the Kennedy pathway toward synthesis of the major membrane phospholipid, phosphatidylcholine (PtdCho)
physiological function
choline kinase (ChoK) phosphorylates choline into phosphocholine. Phosphocholine is important because it a precursor molecule that is utilized in the production of two types of teichoic acids, lipoteichoic acid (LTA) and cell wall teichoic acid (CTA). sChoK plays a role in the growth and pathogenesis for humans of Gram-positive bacterium Streptococcus pneumoniae. In Streptococcus pneumoniae, both acids consist of the same types of polysaccharides but LTA is attached to a lipid and embedded in the cell membrane, and CTA is attached to the peptidoglycan molecules in the cell wall. LTA is an important virulence factor and LTA production has been validated as a drug target
physiological function
choline kinase alpha (ChoKalpha) is an enzyme that is upregulated in many types of cancer and has been shown to be tumorigenic
physiological function
choline kinase catalyzes the initial reaction step of choline metabolism that produces phosphocholine, a prerequisite for the biosynthesis of a primary phospholipid phosphatidylcholine
physiological function
choline kinase catalyzes the initial reaction step of choline metabolism that produces phosphocholine, a prerequisite for the biosynthesis of a primary phospholipid phosphatidylcholine. Arabidopsis thaliana choline/ethanolamine kinase 1 (CEK1) encodes functional CEK that prefers choline than ethanolamine as a substrate in vitro and affects contents of choline and phosphocholine but not phosphatidylcholine in vivo. CEK1 is a primary endoplasmic reticulum-localized choline kinase in vivo that is required for ER stress tolerance possibly through the modulation of choline metabolites
physiological function
choline kinase is linked to cancer malignancy and poor patient prognosis. It is the first enzyme in the Kennedy pathway, ultimately leading to the production of phosphatidylcholine, a key component of biological membranes. Choline kinase exists as two isoforms, alpha (ChoKalpha1 and 2) and beta. Choline kinase alpha also has a non-catalytic protein-binding role and a function in protein-protein interactions. Choline kinase alpha interacts with the SH3 domain of c-Src. This interaction is specific and is mediated by the poly-proline region found N-terminal to the catalytic domain of choline kinase, importance of ChoKalpha1 residues 49-79 for the interaction with the SH3 domain of c-Src. ChoKalpha1 may serve both scaffolding and signaling functions in the context of this oncogenic pathway. The interaction between ChoKalpha1 and the c-Src SH3 domain does not impact the choline kinase enzymatic activity, kinetic analysis, overview. Protein-protein interaction has no influence on enzymatic activity per se
physiological function
the choline kinase of S. pneumoniae (sChoK) is an essential enzyme. Choline kinase (ChoK) phosphorylates choline into phosphocholine. Phosphocholine is important because it a precursor molecule that is utilized in the production of two types of teichoic acids, lipoteichoic acid (LTA) and cell wall teichoic acid (CTA). sChoK plays a role in the growth and pathogenesis for humans of Gram-positive bacterium Streptococcus pneumoniae. In Streptococcus pneumoniae, both acids consist of the same types of polysaccharides but LTA is attached to a lipid and embedded in the cell membrane, and CTA is attached to the peptidoglycan molecules in the cell wall. LTA is an important virulence factor and LTA production has been validated as a drug target
physiological function
-
choline is not a nutritional requirement, but this pathogen does acquire choline from environmental sources and host cells, and produces phosphocholine which, in turn, are used to decorate lipopolysaccharides (LPS). Modified LPS molecules mediate pathogen-host cell interactions allowing the pathogen to evade the host immune system. Choline kinase (ChoK) plays a role in the growth and pathogenesis for humans of Gram-negative bacterium Haemophilus influenzae
-
physiological function
-
choline kinase catalyzes the initial reaction step of choline metabolism that produces phosphocholine, a prerequisite for the biosynthesis of a primary phospholipid phosphatidylcholine
-
physiological function
-
choline kinase catalyzes the initial reaction step of choline metabolism that produces phosphocholine, a prerequisite for the biosynthesis of a primary phospholipid phosphatidylcholine. Arabidopsis thaliana choline/ethanolamine kinase 1 (CEK1) encodes functional CEK that prefers choline than ethanolamine as a substrate in vitro and affects contents of choline and phosphocholine but not phosphatidylcholine in vivo. CEK1 is a primary endoplasmic reticulum-localized choline kinase in vivo that is required for ER stress tolerance possibly through the modulation of choline metabolites
-
physiological function
-
choline is not a nutritional requirement, but this pathogen does acquire choline from environmental sources and host cells, and produces phosphocholine which, in turn, are used to decorate lipopolysaccharides (LPS). Modified LPS molecules mediate pathogen-host cell interactions allowing the pathogen to evade the host immune system. Choline kinase (ChoK) plays a role in the growth and pathogenesis for humans of Gram-negative bacterium Haemophilus influenzae
-
physiological function
-
choline kinase (ChoK) phosphorylates choline into phosphocholine. Phosphocholine is important because it a precursor molecule that is utilized in the production of two types of teichoic acids, lipoteichoic acid (LTA) and cell wall teichoic acid (CTA). sChoK plays a role in the growth and pathogenesis for humans of Gram-positive bacterium Streptococcus pneumoniae. In Streptococcus pneumoniae, both acids consist of the same types of polysaccharides but LTA is attached to a lipid and embedded in the cell membrane, and CTA is attached to the peptidoglycan molecules in the cell wall. LTA is an important virulence factor and LTA production has been validated as a drug target
-
physiological function
-
the choline kinase of S. pneumoniae (sChoK) is an essential enzyme. Choline kinase (ChoK) phosphorylates choline into phosphocholine. Phosphocholine is important because it a precursor molecule that is utilized in the production of two types of teichoic acids, lipoteichoic acid (LTA) and cell wall teichoic acid (CTA). sChoK plays a role in the growth and pathogenesis for humans of Gram-positive bacterium Streptococcus pneumoniae. In Streptococcus pneumoniae, both acids consist of the same types of polysaccharides but LTA is attached to a lipid and embedded in the cell membrane, and CTA is attached to the peptidoglycan molecules in the cell wall. LTA is an important virulence factor and LTA production has been validated as a drug target
-
additional information
analysis of Cho-containing compounds in seedlings by ESI-LC-MS
additional information
analysis of Cho-containing compounds in seedlings by ESI-LC-MS
additional information
analysis of Cho-containing compounds in seedlings by ESI-LC-MS
additional information
analysis of choline-containing compounds in seedlings by ESI-LC-MS
additional information
analysis of choline-containing compounds in seedlings by ESI-LC-MS
additional information
analysis of choline-containing compounds in seedlings by ESI-LC-MS
additional information
ChoKALpha1DELTA49 binding to c-Src-SH3 requires an intact polyproline sequence preceding PL repeats motif but not ChoK kinase activity, two-state induced-fit model, binding analysis with ligand VSL12 (PDB ID 1QWF), overview
additional information
-
ChoKALpha1DELTA49 binding to c-Src-SH3 requires an intact polyproline sequence preceding PL repeats motif but not ChoK kinase activity, two-state induced-fit model, binding analysis with ligand VSL12 (PDB ID 1QWF), overview
additional information
enzyme structure molecular modeling
additional information
-
enzyme structure molecular modeling
additional information
sequence comparison of Streptococcus pneumoniae and human enzymes, overview
additional information
-
sequence comparison of Streptococcus pneumoniae and human enzymes, overview
additional information
substrate binding structure analysis, overview
additional information
-
analysis of Cho-containing compounds in seedlings by ESI-LC-MS
-
additional information
-
analysis of choline-containing compounds in seedlings by ESI-LC-MS
-
additional information
-
sequence comparison of Streptococcus pneumoniae and human enzymes, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ishidate, K.; Furusawa, K.; Nakazawa, Y.
Complete co-purification of choline kinase and ethanolamine kinase from rat kidney and immunological evidence for both kinase activities residing on the same enzyme protein(s) in rat tissues
Biochim. Biophys. Acta
836
119-124
1985
Rattus norvegicus
brenda
Upreti, R.K.; Sanwal, G.G.; Krishnan, P.S.
Likely individuality of the enzymes catalyzing the phosphorylation of choline and ethanolamine
Arch. Biochem. Biophys.
174
658-665
1976
Duttaphrynus melanostictus, Cavia porcellus, Gallus gallus, Columba livia, Hemidactylus sp., Heteropneustes fossilis, Mus musculus, Hoplobatrachus tigerinus, Rattus norvegicus
brenda
Brophy, P.J.; Choy, P.C.; Toone, J.R.; Vance, D.E.
Choline kinase and ethanolamine kinase are separate, soluble enzymes in rat liver
Eur. J. Biochem.
78
491-495
1977
Rattus norvegicus
brenda
Weinhold, P.A.; Rethy, V.B.
The separation, purification, and characterization of ethanolamine kinase and choline kinase from rat liver
Biochemistry
13
5135-5141
1974
Rattus norvegicus
brenda
Spanner, S.; Ansell, G.B.
Choline kinase and ethanolamine kinase activity in the cytoplasm of nerve endings from rat forebrain
Biochem. Soc. Trans.
5
164-165
1977
Rattus norvegicus
brenda
Ramabrahmam, P.; Subrahmanyam, D.
Ethanolamine kinase from Culex pipiens fatigans
Arch. Biochem. Biophys.
207
55-62
1981
Culex quinquefasciatus
brenda
Wittenberg, J.; Kornberg, A.
Choline phosphokinase
J. Biol. Chem.
202
431-444
1953
Saccharomyces cerevisiae
brenda
Uchida, T.; Yamashita, S.
Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase
J. Biol. Chem.
267
10156-10162
1992
Rattus norvegicus
brenda
Hosaka, K.; Tanaka, S.; Nikawa, J.; Yamashita, S.
Cloning of a human choline kinase cDNA by complementation of the yeast cki mutation
FEBS Lett.
304
229-232
1992
Homo sapiens
brenda
Infante, J.P.; Kinsella, J.E.
Phospholipid synthesis in mammary tissue. Choline and ethanolamine kinases: kinetic evidence for two discrete active sites
Lipids
11
727-735
1976
Bos taurus
brenda
Shelley, R.M.; Hodgson, E.
Substrate specificity and inhibition of choline and ethanolamine kinases from the fat body of Phormia rigina larvae
Insect Biochem.
1
149-156
1971
Phormia regina
-
brenda
Hartmann, E.; Schleicher, W.
Isolation and characterization of a choline kinase from Phaseolus vulgaris L. seedlings
Z. Pflanzenphysiol.
83
69-80
1977
Phaseolus vulgaris
-
brenda
Haubrich, D.R.
Partial purification and properties of choline kinase (EC 2. 7. 1. 32) from rabbit brain: measurement of acetylcholine
J. Neurochem.
21
315-328
1973
Oryctolagus cuniculus
brenda
Ramabrahamam, P.; Subrahmanaym, D.
Choline kinase of Culex pipiens fatigans
Insect Biochem.
9
315-321
1979
Culex quinquefasciatus
-
brenda
Uchida, T.; Yamashita, S.
Purification and properties of choline kinase from rat brain
Biochim. Biophys. Acta
1043
281-288
1990
Rattus norvegicus
brenda
Ishidate, K.; Nakagomi, K.; Nakazawa, Y.
Complete purification of choline kinase from rat kidney and preparation of rabbit antibody against rat kidney choline kinase
J. Biol. Chem.
259
14706-14710
1984
Rattus norvegicus
brenda
Brostrom, M.A.; Browning, E.T.
Choline kinase from brewers yeast. Partial purification, properties, and kinetic mechanism
J. Biol. Chem.
248
2364-2371
1973
Saccharomyces cerevisiae
brenda
Setty, P.N.; Krishnan, P.S.
Choline kinase in Cuscuta reflexa
Biochem. J.
126
313-324
1972
Cuscuta reflexa
brenda
Clary, G.L.; Tsai, C.F.; Guynn, R.W.
Substrate specificity of choline kinase
Arch. Biochem. Biophys.
254
214-221
1987
Saccharomyces cerevisiae
brenda
Kinney, A.J.; Moore, T.S.
Phosphatidylcholine synthesis in castor bean endosperm: characteristics and reversibility of the choline kinase reaction
Arch. Biochem. Biophys.
260
102-108
1988
Ricinus communis
brenda
Hock, K.; Hartmann, E.
Localization of phosphatidylcholine synthesizing enzymes in etiolated bean seedlings (Phaseolus vulgaris L.)
Plant Sci. Lett.
21
389-396
1981
Phaseolus vulgaris
-
brenda
Fukuyama, H.; Yamashita, S.
Activation of rat liver choline kinase by polyamines
FEBS Lett.
71
33-36
1976
Rattus norvegicus
-
brenda
Kariya, Y.; Kimura, A.; Aisaka, K.; Tochikura, T.
Isolation and purification of choline kinase from Hansenula jadinii
J. Ferment. Technol.
58
489-492
1980
Cyberlindnera jadinii
-
brenda
Porter, T.J.; Kent, C.
Purification and characterization of choline/ethanolamine kinase from rat liver
J. Biol. Chem.
265
414-422
1990
Rattus norvegicus
brenda
Ulane, R.E.; Stephenson, L.L.; Farrell, P.M.
Evidence for the existence of a single enzyme catalyzing the phosphorylation of choline and ethanolamine in primate lung
Biochim. Biophys. Acta
531
295-300
1978
Chlorocebus aethiops
brenda
Porter, T.J.; Kent, C.
Choline/ethanolamine kinase from rat liver
Methods Enzymol.
209
134-146
1992
Rattus norvegicus
brenda
Uchida, T.; Yamashita, S.
Choline/ethanolamine kinase from rat brain
Methods Enzymol.
209
147-153
1992
Rattus norvegicus
brenda
Ishidate, K.; Nakazawa, Y.
Choline/ethanolamine kinase from rat kidney
Methods Enzymol.
209
121-134
1992
Rattus norvegicus
brenda
Hernandez-Alcoceba, R.; Fernandez, F.; Lacal, J.C.
In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery
Cancer Res.
59
3112-3118
1999
Homo sapiens
brenda
Yamashita, S.; Hosaka, K.
Choline kinase from yeast
Biochim. Biophys. Acta
1348
63-69
1997
Saccharomyces cerevisiae
brenda
Gee, P.; Kent, C.
Multiple isoforms of choline kinase from Caenorhabditis elegans: cloning, expression, purification, and characterization
Biochim. Biophys. Acta
1648
33-42
2003
Caenorhabditis elegans
brenda
Yu, Y.; Sreenivas, A.; Ostrander, D.B.; Carman, G.M.
Phosphorylation of Saccharomyces cerevisiae Choline Kinase on Ser30 and Ser85 by Protein Kinase A Regulates Phosphatidylcholine Synthesis by the CDP-choline Pathway
J. Biol. Chem.
277
34978-34986
2002
Saccharomyces cerevisiae
brenda
Kim, K.H.; Voelker, D.R.; Flocco, M.T.; Carman, G.M.
Expression, purification, and characterization of choline kinase, product of the CKI gene from Saccharomyces cerevisiae
J. Biol. Chem.
273
6844-6852
1998
Saccharomyces cerevisiae
brenda
Aoyama, C.; Ohtani, A.; Ishidate, K.
Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver
Biochem. J.
363
777-784
2002
Mus musculus
brenda
Ishidate, K.
Choline/ethanolamine kinase from mammalian tissues
Biochim. Biophys. Acta
1348
70-78
1997
Homo sapiens, Rattus norvegicus
brenda
Al-Malki, A.; Morby, A.; Harwood, J.L.
Pea choline kinase: purification, properties and isolation of a cDNA
Biochem. Soc. Trans.
28
721-723
2000
Pisum sativum
brenda
Liu, Y.; Ekambaram, M.C.; Blum, P.S.; Stimbert, C.D.; Jernigan, H.M., Jr.
Galactosemic cataractogenesis disrupts intracellular interactions and changes the substrate specificity of choline/ethanolamine kinase
Exp. Eye Res.
67
193-202
1998
Rattus norvegicus
brenda
Menten, J.F.M.; Pesti, G.M.
The determination of the choline content of feed ingredients using choline kinase
J. Sci. Food Agric.
78
395-398
1998
Brassica sp., Glycine max, Zea mays
brenda
Aoyama, C.; Yamazaki, N.; Terada, H.; Ishidate, K.
Structure and characterization of the genes for murine choline/ethanolamine kinase isozymes alpha and beta
J. Lipid Res.
41
452-464
2000
Mus musculus (O54804), Mus musculus
brenda
Peisach, D.; Gee, P.; Kent, C.; Xu, Z.
The crystal structure of choline kinase reveals a eukaryotic protein kinase fold
Structure
11
703-713
2003
Caenorhabditis elegans
brenda
Cao, Z.M.; Kanfer, J.N.
Partial purification of two forms of choline kinase and separation of choline kinase from sphingosine kinase of rat brain
Neurochem. Res.
20
643-649
1995
Rattus norvegicus
brenda
Tasseva, G.; Richard, L.; Zachowski, A.
Regulation of phosphatidylcholine biosynthesis under salt stress involves choline kinases in Arabidopsis thaliana
FEBS Lett.
566
115-120
2004
Arabidopsis thaliana
brenda
Yuan, C.; Kent, C.
Identification of critical residues of ATP kinase A2 from Caenorhabditis elegans
J. Biol. Chem.
279
17801-17809
2004
Caenorhabditis elegans
brenda
Rodriguez-Gonzalez, A.; Ramirez de Molina, A.; Benitez-Rajal, J.; Lacal, J.C.
Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets
Prog. Cell Cycle Res.
5
191-201
2003
Mus musculus (Q54AG5), Homo sapiens (Q9Y259)
brenda
Aoyama, C.; Liao, H.; Ishidate, K.
Structure and function of choline kinase isoforms in mammalian cells
Prog. Lipid Res.
43
266-281
2004
Saccharomyces cerevisiae, Caenorhabditis elegans, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Al-Saeedi, F.; Smith, T.; Welch, A.
[Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay
Anticancer Res.
27
901-906
2007
Homo sapiens
brenda
Choubey, V.; Maity, P.; Guha, M.; Kumar, S.; Srivastava, K.; Puri, S.K.; Bandyopadhyay, U.
Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism
Antimicrob. Agents Chemother.
51
696-706
2007
Plasmodium falciparum
brenda
Choubey, V.; Guha, M.; Maity, P.; Kumar, S.; Raghunandan, R.; Maulik, P.R.; Mitra, K.; Halder, U.C.; Bandyopadhyay, U.
Molecular characterization and localization of Plasmodium falciparum choline kinase
Biochim. Biophys. Acta
1760
1027-1038
2006
Plasmodium falciparum
brenda
Liao, H.; Aoyama, C.; Ishidate, K.; Teraoka, H.
Deletion and alanine mutation analyses for the formation of active homo- or hetero-dimer complexes of mouse choline kinase-alpha and -beta
Biochim. Biophys. Acta
1761
111-120
2006
Mus musculus
brenda
Glunde, K.; Raman, V.; Mori, N.; Bhujwalla, Z.M.
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation
Cancer Res.
65
11034-11043
2005
Homo sapiens
brenda
Milanese, L.; Espinosa, A.; Campos, J.M.; Gallo, M.A.; Entrena, A.
Insight into the inhibition of human choline kinase: homology modeling and molecular dynamics simulations
ChemMedChem
1
1216-1228
2006
Caenorhabditis elegans, Homo sapiens
brenda
Janardhan, S.; Srivani, P.; Sastry, G.N.
Choline kinase: an important target for cancer
Curr. Med. Chem.
13
1169-1186
2006
Saccharomyces cerevisiae, Caenorhabditis elegans, Homo sapiens, Mus musculus, Rattus norvegicus, Schizosaccharomyces pombe
brenda
Campos, J.M.; Sanchez-Martin, R.M.; Conejo-Garcia, A.; Entrena, A.; Gallo, M.A.; Espinosa, A.
(Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs
Curr. Med. Chem.
13
1231-1248
2006
Homo sapiens
brenda
Conejo-Garcia, A.; Entrena, A.; Campos, J.M.; Sanchez-Martin, R.M.; Gallo, M.A.; Espinosa, A.
Towards a model for the inhibition of choline kinase by a new type of inhibitor
Eur. J. Med. Chem.
40
315-319
2005
Homo sapiens
brenda
Rodriguez-Gonzalez, A.; Ramirez de Molina, A.; Banez-Coronel, M.; Megias, D.; Lacal, J.C.
Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism
Int. J. Oncol.
26
999-1008
2005
Homo sapiens
brenda
Choi, M.G.; Kurnov, V.; Kersting, M.C.; Sreenivas, A.; Carman, G.M.
Phosphorylation of the yeast choline kinase by protein kinase C. Identification of Ser25 and Ser30 as major sites of phosphorylation
J. Biol. Chem.
280
26105-26112
2005
Saccharomyces cerevisiae, Saccharomyces cerevisiae KS106
brenda
Malito, E.; Sekulic, N.; Too, W.C.; Konrad, M.; Lavie, A.
Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine
J. Mol. Biol.
364
136-151
2006
Homo sapiens (P35790), Homo sapiens
brenda
Gibellini, F.; Hunter, W.N.; Smith, T.K.
Biochemical characterization of the initial steps of the Kennedy pathway in Trypanosoma brucei: the ethanolamine and choline kinases
Biochem. J.
415
135-144
2008
Trypanosoma brucei
brenda
Aoyama, C.; Ishidate, K.; Sugimoto, H.; Vance, D.E.
Induction of choline kinase alpha by carbon tetrachloride (CCl4) occurs via increased binding of c-jun to an AP-1 element
Biochim. Biophys. Acta
1771
1148-1155
2007
Mus musculus, Mus musculus (O54804)
brenda
Mori, N.; Glunde, K.; Takagi, T.; Raman, V.; Bhujwalla, Z.M.
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells
Cancer Res.
67
11284-11290
2007
Homo sapiens
brenda
Glunde, K.; Shah, T.; Winnard, P.T.; Raman, V.; Takagi, T.; Vesuna, F.; Artemov, D.; Bhujwalla, Z.M.
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model
Cancer Res.
68
172-180
2008
Homo sapiens
brenda
Ramirez de Molina, A.; Gallego-Ortega, D.; Sarmentero-Estrada, J.; Lagares, D.; Gomez Del Pulgar, T.; Bandres, E.; Garcia-Foncillas, J.; Lacal, J.C.
Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy
Int. J. Biochem. Cell Biol.
40
1753-1763
2008
Homo sapiens
brenda
Soto, A.; Carman, G.M.
Regulation of the Saccharomyces cerevisiae CKI1-encoded choline kinase by zinc depletion
J. Biol. Chem.
283
10079-10088
2008
Saccharomyces cerevisiae
brenda
Aoyama, C.; Young, S.G.; Vance, D.E.
Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis
J. Biol. Chem.
283
1456-1462
2008
Mus musculus
brenda
Ramirez de Molina, A.; Sarmentero-Estrada, J.; Belda-Iniesta, C.; Taron, M.; Ramirez de Molina, V.; Cejas, P.; Skrzypski, M.; Gallego-Ortega, D.; de Castro, J.; Casado, E.; Garcia-Cabezas, M.A.; Sanchez, J.J.; Nistal, M.; Rosell, R.; Gonzalez-Baron, M.; Lacal, J.C.
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study
Lancet Oncol.
8
889-897
2007
Homo sapiens
brenda
Alberge, B.; Gannoun-Zaki, L.; Bascunana, C.; Tran van Ba, C.; Vial, H.; Cerdan, R.
Comparison of the cellular and biochemical properties of Plasmodium falciparum choline and ethanolamine kinases
Biochem. J.
425
149-158
2010
Plasmodium falciparum 3D7 (Q8IM71)
brenda
Srivani, P.; Sastry, G.N.
Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds
J. Mol. Graph. Model.
27
676-688
2009
Homo sapiens (P35790)
brenda
Elswaifi, S.F.; St Michael, F.; Sreenivas, A.; Cox, A.; Carman, G.M.; Inzana, T.J.
Molecular characterization of phosphorylcholine expression on the lipooligosaccharide of Histophilus somni
Microb. Pathog.
47
223-230
2009
Histophilus somni (B0URY8), Histophilus somni
brenda
Ross, J.; Najjar, A.M.; Sankaranarayanapillai, M.; Tong, W.P.; Kaluarachchi, K.; Ronen, S.M.
Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine
Mol. Cancer Ther.
7
2556-2565
2008
Homo sapiens
brenda
Chua, B.T.; Gallego-Ortega, D.; Ramirez de Molina, A.; Ullrich, A.; Lacal, J.C.; Downward, J.
Regulation of Akt(ser473)phosphorylation by Choline kinase in breast carcinoma cells
Mol. Cancer
8
131
2009
Homo sapiens
brenda
Nimmagadda, S.; Glunde, K.; Pomper, M.G.; Bhujwalla, Z.M.
Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells
Neoplasia
11
477-484
2009
Homo sapiens
brenda
Yalcin, A.; Clem, B.; Makoni, S.; Clem, A.; Nelson, K.; Thornburg, J.; Siow, D.; Lane, A.N.; Brock, S.E.; Goswami, U.; Eaton, J.W.; Telang, S.; Chesney, J.
Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling
Oncogene
29
139-149
2009
Homo sapiens
brenda
Gallego-Ortega, D.; Ramirez de Molina, A.; Ramos, M.A.; Valdes-Mora, F.; Barderas, M.G.; Sarmentero-Estrada, J.; Lacal, J.C.
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment
PLoS ONE
4
e7819
2009
Homo sapiens (P35790), Homo sapiens (Q9Y259), Homo sapiens
brenda
Sahun-Roncero, M.; Rubio-Ruiz, B.; Saladino, G.; Conejo-Garcia, A.; Espinosa, A.; Velazquez-Campoy, A.; Gervasio, F.L.; Entrena, A.; Hurtado-Guerrero, R.
The mechanism of allosteric coupling in choline kinase alpha1 revealed by the action of a rationally designed inhibitor
Angew. Chem. Int. Ed. Engl.
52
4582-4586
2013
Helicobacter pylori
brenda
Wu, G.; Sher, R.; Cox, G.; Vance, D.
Differential expression of choline kinase isoforms in skeletal muscle explains the phenotypic variability in the rostrocaudal muscular dystrophy mouse
Biochim. Biophys. Acta
1801
446-454
2010
Mus musculus
brenda
Hudson, C.S.; Knegtel, R.M.; Brown, K.; Charlton, P.A.; Pollard, J.R.
Kinetic and mechanistic characterisation of choline kinase-alpha
Biochim. Biophys. Acta
1834
1107-1116
2013
Homo sapiens (P35790), Homo sapiens
brenda
Rubio-Ruiz, B.; Conejo-Garcia, A.; Rios-Marco, P.; Carrasco-Jimenez, M.P.; Segovia, J.; Marco, C.; Gallo, M.A.; Espinosa, A.; Entrena, A.
Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors
Eur. J. Med. Chem.
50
154-162
2012
Homo sapiens (P35790)
brenda
Gruber, J.; See Too, W.C.; Wong, M.T.; Lavie, A.; McSorley, T.; Konrad, M.
Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy
FEBS J.
279
1915-1928
2012
Homo sapiens
brenda
Hong, B.S.; Allali-Hassani, A.; Tempel, W.; Finerty, P.J.; Mackenzie, F.; Dimov, S.; Vedadi, M.; Park, H.W.
Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity
J. Biol. Chem.
285
16330-16340
2010
Homo sapiens (P35790), Homo sapiens (Q9Y259), Homo sapiens
brenda
Sampels, V.; Hartmann, A.; Dietrich, I.; Coppens, I.; Sheiner, L.; Striepen, B.; Herrmann, A.; Lucius, R.; Gupta, N.
Conditional mutagenesis of a novel choline kinase demonstrates plasticity of phosphatidylcholine biogenesis and gene expression in Toxoplasma gondii
J. Biol. Chem.
287
16289-16299
2012
Toxoplasma gondii
brenda
Bansal, A.; Harris, R.A.; DeGrado, T.R.
Choline phosphorylation and regulation of transcription of choline kinase alpha in hypoxia
J. Lipid Res.
53
149-157
2012
Homo sapiens
brenda
Miyake, T.; Parsons, S.J.
Functional interactions between choline kinase alpha, epidermal growth factor receptor and c-Src in breast cancer cell proliferation
Oncogene
31
1431-1441
2012
Homo sapiens (P35790)
brenda
Li, Z.; Wu, G.; van der Veen, J.N.; Hermansson, M.; Vance, D.E.
Phosphatidylcholine metabolism and choline kinase in human osteoblasts
Biochim. Biophys. Acta
1841
859-867
2014
Homo sapiens (P35790), Homo sapiens
brenda
Schiaffino-Ortega, S.; Lopez-Cara, L.C.; Rios-Marco, P.; Carrasco-Jimenez, M.P.; Gallo, M.A.; Espinosa, A.; Marco, C.; Entrena, A.
New non-symmetrical choline kinase inhibitors
Bioorg. Med. Chem.
21
7146-7154
2013
Homo sapiens (P35790)
brenda
Rubio-Ruiz, B.; Figuerola-Conchas, A.; Ramos-Torrecillas, J.; Capitan-Canadas, F.; Rios-Marco, P.; Carrasco, M.P.; Gallo, M.A.; Espinosa, A.; Marco, C.; Ruiz, C.; Entrena, A.; Hurtado-Guerrero, R.; Conejo-Garcia, A.
Discovery of a new binding site on human choline kinase alpha1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivatives
J. Med. Chem.
57
507-515
2014
Homo sapiens (P35790), Homo sapiens
brenda
Zech, S.G.; Kohlmann, A.; Zhou, T.; Li, F.; Squillace, R.M.; Parillon, L.E.; Greenfield, M.T.; Miller, D.P.; Qi, J.; Thomas, R.M.; Wang, Y.; Xu, Y.; Miret, J.J.; Shakespeare, W.C.; Zhu, X.; Dalgarno, D.C.
Novel small molecule inhibitors of choline kinase identified by fragment-based drug discovery
J. Med. Chem.
59
671-686
2016
Homo sapiens (P35790), Homo sapiens
brenda
Trousil, S.; Carroll, L.; Kalusa, A.; Aberg, O.; Kaliszczak, M.; Aboagye, E.O.
Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors
MedChemComm
2013
693-696
2013
Homo sapiens
brenda
Mori, N.; Gadiya, M.; Wildes, F.; Krishnamachary, B.; Glunde, K.; Bhujwalla, Z.M.
Characterization of choline kinase in human endothelial cells
NMR Biomed.
26
1501-1507
2013
Homo sapiens (P35790), Homo sapiens
brenda
Wang, L.; Jiang, Y.L.; Zhang, J.R.; Zhou, C.Z.; Chen, Y.
Structural and enzymatic characterization of the choline kinase LicA from Streptococcus pneumoniae
PLoS ONE
10
e0120467
2015
Streptococcus pneumoniae (Q8DPI4), Streptococcus pneumoniae
brenda
Chang, C.C.; Few, L.L.; Konrad, M.; See Too, W.C.
Phosphorylation of human choline kinase beta by protein kinase A: its impact on activity and inhibition
PLoS ONE
11
e0154702
2016
Homo sapiens (Q9Y259), Homo sapiens
brenda
Schiaffino-Ortega, S.; Baglioni, E.; Mariotto, E.; Bortolozzi, R.; Serran-Aguilera, L.; Rios-Marco, P.; Carrasco-Jimenez, M.P.; Gallo, M.A.; Hurtado-Guerrero, R.; Marco, C.; Basso, G.; Viola, G.; Entrena, A.; Lopez-Cara, L.C.
Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human choline kinase alpha1 (ChoKalpha1)
Sci. Rep.
6
23793
2016
Homo sapiens (P35790), Homo sapiens
brenda
Kall, S.L.; Delikatny, E.J.; Lavie, A.
Identification of a unique inhibitor-binding site on choline kinase alpha
Biochemistry
57
1316-1325
2018
Homo sapiens (P35790)
brenda
Torretta, A.; Lopez-Cara, L.; Parisini, E.
Crystal structure of the apo and the adp-bound form of choline kinase from Plasmodium falciparum
Crystals
10
1-13
2020
Plasmodium falciparum (Q8IM71)
-
brenda
Zimmerman, T.; Lacal, J.C.; Ibrahim, S.A.
Choline kinase emerges as a promising drug target in Gram-positive bacteria
Front. Microbiol.
6
2146
2019
Haemophilus influenzae (P14181), Haemophilus influenzae, Streptococcus pneumoniae (Q8DPI4), Streptococcus pneumoniae, Haemophilus influenzae R6 (P14181), Haemophilus influenzae ATCC BAA-255 (P14181), Streptococcus pneumoniae ATCC BAA-255 (Q8DPI4)
brenda
Zech, S.; Kohlmann, A.; Zhou, T.; Li, F.; Squillace, R.; Parillon, L.; Greenfield, M.; Miller, D.; Qi, J.; Thomas, R.; Wang, Y.; Xu, Y.; Miret, J.; Shakespeare, W.; Zhu, X.; Dalgarno, D.
Novel small molecule inhibitors of choline kinase identified by fragment-based drug discovery
J. Med. Chem.
59
671-686
2016
Homo sapiens (O54804), Homo sapiens
brenda
Rubio-Ruiz, B.; Rixados-Marco, P.; Carrasco-Jimenez, M.; Espinosa, A.; Hurtado-Guerrero, R.; Marco, C.; Conejo-Garcixada, A.; Entrena, A.
Choline kinase inhibition and docking studies of a series of 6-(benzylthio)-9H-purin-9-yl-pyridinium derivatives
Med. Chem. Res.
26
2809-2815
2017
Homo sapiens (O54804)
-
brenda
Lin, Y.C.; Kanehara, K.; Nakamura, Y.
Arabidopsis CHOLINE/ETHANOLAMINE KINASE 1 (CEK1) is a primary choline kinase localized at the endoplasmic reticulum (ER) and involved in ER stress tolerance
New Phytol.
223
1904-1917
2019
Arabidopsis thaliana (Q8L518), Arabidopsis thaliana (Q9M9H6), Arabidopsis thaliana (Q9SZ92), Arabidopsis thaliana Col-0 (Q8L518), Arabidopsis thaliana Col-0 (Q9M9H6), Arabidopsis thaliana Col-0 (Q9SZ92)
brenda
Zimmerman, T.; Chasten, V.; Lacal, J.C.; Ibrahim, S.A.
Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae
Sci. Rep.
10
15418
2020
Streptococcus pneumoniae (Q8DPI4), Streptococcus pneumoniae, Streptococcus pneumoniae ATCC BAA-255 (Q8DPI4)
brenda
Kall, S.L.; Whitlatch, K.; Smithgall, T.E.; Lavie, A.
Molecular basis for the interaction between human choline kinase alpha and the SH3 domain of the c-Src tyrosine kinase
Sci. Rep.
9
17121
2019
Homo sapiens (P35790), Homo sapiens
brenda
Pulido, S.A.; Nguyen, V.H.; Alzate, J.F.; Cedeno, D.L.; Makurath, M.A.; Rios-Vasquez, A.; Duque-Benitez, S.M.; Jones, M.A.; Robledo, S.M.; Friesen, J.A.
Insights into the phosphatidylcholine and phosphatidylethanolamine biosynthetic pathways in Leishmania parasites and characterization of a choline kinase from Leishmania infantum
Comp. Biochem. Physiol. B
213
45-54
2017
Leishmania infantum (A4IB50), Leishmania infantum, Leishmania infantum JPCM5 (A4IB50)
brenda